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ABSTRACT 
 
This dissertation investigated the role of two therapeutic interventions (exercise training 
and hormone replacement therapy) on two different states of endothelial dysfunction, 
chronic coronary occlusion and aging. Despite remarkable evidence for the therapeutic 
benefits of physical activity, the mechanisms by which regular exercise improves 
vascular function in the setting of coronary artery disease are not fully understood. 
Similarly, the effects of aging and hormone replacement therapy on vascular function are 
often paradoxical and poorly understood. Thus, the first project utilized a model of 
chronic coronary artery occlusion to evaluate the effects of exercise training on cellular 
and molecular adaptations of collateral-dependent coronary vasculature compared to the 
nonoccluded control.  This study provided new evidence that exercise training 
concomitantly enhanced the contributions of multiple vasodilator mechanisms, including 
nitric oxide, prostacyclin and BKCa channels to vascular function in the ischemic heart. 
Increased contribution of multiple vasodilator signaling pathways after exercise training 
appears to promote compensation or redundancy to ensure adequate vasodilation and 
coronary vascular blood flow.  The second project utilized a model of aging to evaluate 
the interactive effects of age and hormone replacement therapy on the cellular and 
molecular mechanisms underlying the regulation of cerebrovascular function. Although 
the mechanisms underlying the beneficial effects of estrogen on cerebrovascular 
function have been studied at length, the mechanisms responsible for age-dependent 
deleterious effects of estrogen are largely unknown. The results of this study revealed 
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that estrogen exerts divergent effects on the cerebrovasculature with advancing age.  In 
younger females, estrogen replacement treatment is beneficial, attenuating 
vasoconstriction primarily by the COX-1 dependent prostanoid pathway and increased 
PGI2 production. In contrast, in older reproductively senescent females, estrogen 
augmented vasoconstriction via the COX-2 dependent prostanoid pathway and increased 
TXA2 production. A better understanding the mechanisms by which estrogen exerts 
beneficial versus detrimental effects on the cerebrovasculature may lead to new gender-
specific therapeutic agents designed specifically to target the cerebrovascular system and 
other estrogen-responsive tissues. 
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GPR30 G-protein coupled estrogen receptor 30 
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HRT hormone replacement therapy 
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K
+
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KCa calcium-dependent potassium channel 
LAD left anterior descending artery 
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L-NAME N
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-nitro-L-arginine methyl ester 
LO lipoxygenase 
LT leukotrienes 
MA mature multigravid adult 
MCA middle cerebral artery 
MPA medroxyprogesterone acetate 
MPN medial preoptic nucleus 
NADPH nicotinamide adenine dinucleotide phosphate 
nNOS neuronal nitric oxide synthase 
NO nitric oxide 
NOS nitric oxide synthase 
PCI percutaneous coronary intervention 
p-eNOS phosphorylated eNOS 
PG prostaglandin 
PGD2 prostaglandin D2  
PGE2 prostaglandin E2  
6-keto PGF1α 6- keto prostaglandin F1α, stable metabolite of PGI2  
PGF2α prostaglandin F2α 
PGH2 prostaglandin H2  
PGI2 prostacyclin, prostaglandin I2 
PGIS prostacyclin synthase 
PI3K phosphoinositide 3-kinase 
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PLA2 phospholipase A2 
ROS reactive oxygen species 
RS reproductively senescent 
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VEGF vascular endothelial growth factor 
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1. INTRODUCTION  
 
1.1. Vascular endothelium 
1.1.1. Endothelial function in health 
The vascular endothelium is a single layer of endothelial cells which lines the inner 
surface of all blood vessels and separates the circulating blood from the surrounding 
vascular wall. The endothelium not only provides a structural barrier between the 
circulating blood and surrounding tissues, but is also involved in the regulation of a 
number of important vascular functions including thrombosis, smooth muscle cell 
proliferation, vascular tone, cell migration, leukocyte adhesion, and inflammatory 
responses. Endothelial cells secrete a number of vasoactive mediators that influence 
vascular structure and function. These mediators regulate local blood flow and systemic 
blood pressure by acting in a paracrine manner to alter the contractile state of the 
underlying smooth muscle and the resultant vascular tone (Feletou et al., 2006; 
Landmesser et al., 2004; Vane et al., 1990; Vanhoutte et al., 2009).   
 
1.1.2. Endothelial-derived vasoactive mediators 
In response to mechanical or humoral stimuli, the endothelium releases agents that 
regulate vascular function (Figure 1). The most common vasodilator substances 
produced by the endothelium are nitric oxide, prostacyclin (PGI2), endothelium-derived 
hyperpolarizing factors (EDHF), and C-type natriuretic peptide (CNP). Common 
vasoconstrictors include endothelin (ET), angiotensin II (ANG II), thromboxane A2 
 2 
 
(TXA2), and reactive oxygen species (ROS). The release of nitric oxide and other 
vascular mediators by endothelial cells can be modulated by both acute and chronic 
factors. Enhanced secretion or up-regulation of vascular mediators occurs via increased 
shear stress, hormones, exercise, and diet, while decreased secretion or down-regulation 
occurs via oxidative stress, smoking, obesity, and vascular diseases (Vanhoutte et al., 
2009). 
 
 
 
Figure 1. Endothelium-derived relaxing and contracting factors and their effects on vascular smooth 
muscle. 
 
 
 
 
Endothelial Cells
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PGI2 NO H2O2 K
+ EET PGH2/TXA2 O2
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1.1.2.1. Nitric oxide 
One of the most studied endothelium-derived vasodilators is nitric oxide. It is 
synthesized by the vascular endothelium, and acts as a key modulator of endothelial 
function, regulating vascular tone and local blood flow. It also inhibits platelet 
aggregation, limits vascular platelet, leukocyte, and monocyte adhesion, and suppresses 
vascular smooth muscle cell migration and proliferation (Forstermann et al., 2006; 
Landmesser et al., 2004; Moncada et al., 1993; Urakami-Harasawa et al., 1997). Nitric 
oxide is synthesized from L-arginine by a family of nitric oxide synthase (NOS) 
enzymes. The three distinct isoforms of NOS, endothelial (eNOS), neuronal (nNOS) and 
inducible (iNOS), differ in both structure and function (Marletta, 1993). The main source 
of endothelial nitric oxide occurs by the way of constitutively expressed eNOS in 
endothelial cells, but the enzyme is also found in cardiomyocytes, platelets, and cardiac 
conduction tissue. Nitric oxide stimulates soluble guanylyl cyclase in the underlying 
smooth muscle cells, thereby increasing the production of cyclic guanosine 
monophosphate (cGMP), and causing vasodilation (Forstermann et al., 1994; Sase et al., 
1997).  
 
NOS is a multi-domain enzyme containing a C-terminal reductase domain that binds 
nicotinamide adenine dinucleotide phosphate (NADPH) and a heme-containing N-
terminal oxygenase domain that binds the cofactor BH4, molecular O2, and the substrate 
L-arginine. In order to be functional, NOS forms dimers composed of two identical 
subunits. All isoforms of NOS catalyze electron transfer from NADPH on the C-terminal 
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to the heme on the N-terminal, consequently activating O2, and synthesizing nitric oxide. 
Calcium (Ca
2+
)-induced binding of calmodulin (CaM) to the enzymeincreases electron 
transfer thus enhancing nitric oxide production (Corson et al., 1996; Forstermann et al., 
1994; Forstermann et al., 2006). This Ca
2+
-dependent stimulation of CaM is not the only 
regulator of eNOS enzyme activity. (Fleming et al., 1998; Forstermann et al., 2006). It is 
also regulated by post-translational modification, such as phosphorylation and 
dephosphorylation of eNOS, and interactions with several regulatory proteins, including 
heat shock protein 90. Numerous kinases phosphorylate eNOS, resulting in increased or 
decreased nitric oxide production, including: serine/threonine protein kinase Akt/PKB, 
AMP-activated protein kinase, protein kinase G, protein kinase A, and CaM-dependent 
protein kinases II (Boo et al., 2003; Dimmeler et al., 1999; Govers et al., 2001). 
 
1.1.2.2. Arachidonic metabolism 
Arachidonic acid (AA) is the most common fatty acid present in the phospholipids of the 
cell membrane. When the cell membrane is stimulated by physical or humoral stimuli, 
AA is released by phospholipase A2 (PLA2) or by diacylglycerol (DAG) lipase into the 
cytosol. Here, it undergoes further metabolism via one of the following pathways: 1) the 
cyclooxygenase (COX) pathway, which produces the prostaglandins (PGs); 2) the 
lipoxygenase (LO) pathway, which gives rise to the leukotrienes and several 
hydroperoxides; or 3) the cytochrome P450 (CYP) pathway, which forms the 
epoxyeicosatrienoic acids (EETs) and ω-hydroxyeicosatetraenoic acid (HETEs) 
(Capdevila et al., 2000; Needleman et al., 1986) (Figure 2).  
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Figure 2. The three pathways of arachidonic acid metabolism. 
 
 
1.1.2.2.1. Cyclooxygenase pathway 
The two main isoforms of COX (COX-1/COX-2) are expressed constitutively in 
endothelial and vascular smooth muscle cells (20 fold higher expression in 
endothelium), and are both inducible by physical and/or humoral stimuli, such as shear 
stress (Doroudi et al., 2000; Topper et al., 1996). Recently a third COX enzyme, COX-3, 
was discovered. It is encoded by the same gene as COX-1 but retains an intron and thus 
is not functional in humans (Botting, 2003).  
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COX-1 is the better known constitutive form of the enzyme, as it is found in many 
tissues, including the vascular endothelium and platelets (Wallace, 1999). It is a 
housekeeping gene involved in the maintenance of physiological homeostasis (Smith et 
al., 1996) . Because of the comparatively low levels of COX-2 expression, it was 
previously thought to be only inducible. However, recent studies have shown that it has 
an important regulatory role in the control of tissue function under various physiological 
states and is constitutively expressed in the heart, brain, kidneys, spinal cord, 
vasculature, and lung (Li et al., 2005; Parente et al., 2003; Wallace, 1999).  
Prostaglandins act on a wide array of cells and exert a variety of effects including 
modulation/regulation of vascular smooth muscle cells, platelet aggregation, 
inflammatory processes, calcium movement, cell growth, thermoregulation, glomerular 
filtration rate, stomach acid secretion, and induction of labor. 
 
There are six major COX derived prostanoids produced in the endothelium: 
prostaglandin H2 (PGH2), prostaglandin I2 (PGI2, prostacyclin), prostaglandin E2 (PGE2), 
prostaglandin F2α (PGF2α), prostaglandin D2 (PGD2), and thromboxane A2 (TXA2) 
(Nakahata, 2008; Weeks, 1972). Although not definitive, in most tissues PGI2, and PGD2 
act as vasodilators (Moncada et al., 1979), PGH2, PGF2α, and TXA2 act as 
vasoconstrictors (Gluais et al., 2005; Gluais et al., 2006), and PGE2 can act as either a 
dilator or constrictor, depending on tissue type, concentration, and receptor subtypes 
present (Carter et al., 1986; Gluais et al., 2005; Weeks, 1972). Prostaglandins are 
synthesized in almost all tissues, and the dominant PG synthesized in each tissue varies 
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with the enzymes that predominate. For example, PGI2 is the most common PG in the 
vascular endothelium, while TXA2 is the primary PG in the platelet (Chan et al., 1986). 
These PGs are local mediators, acting in both autocrine and paracrine fashions, at or near 
their site of synthesis to trigger a vast array of biological signals, including vasodilation, 
vasoconstriction, and platelet aggregation (Moncada et al., 1979; Nakahata, 2008; 
Parente et al., 2003; Wallace, 1999; Weeks, 1972).  
 
1.1.2.2.1.1. Prostaglandin H2 (PGH2) 
Both COX-1 and COX-2 convert AA to PGH2 in the cytosol. PGH2, the common 
prostaglandin endoperoxide precursor of all PGs, is then further transformed by specific 
terminal synthases: thromboxane synthase (TXS) for TXA2, prostacyclin synthase 
(PGIS) for PGI2, and prostaglandin D-isomerase, prostaglandin E-isomerase, and 
prostaglandin F-reductase for PGD2, PGE2, and PGF2α, respectively. Importantly, in 
addition to its role as a common PG precursor, untransformed PGH2 can interact at the 
TXA2 receptor (TP) to induce vasoconstriction and platelet aggregation (Dai et al., 1992; 
Feletou et al., 2009; Hynes et al., 1987; Lin et al., 1994; Pagano et al., 1991). 
 
1.1.2.2.1.2. Prostaglandin I2/Prostacyclin (PGI2) 
PGI2 is synthesized by its terminal enzyme, PGI synthase (PGIS), in the vascular 
endothelium and vascular smooth muscle (Flavahan, 2007). The endothelium is the site 
for the majority of PGI2 biosynthesis. PGIS is expressed in the vascular endothelium at 
much higher levels (5-100 fold) than any other terminal PG synthase, and as a result, 
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PGI2 is the most abundantly produced prostanoid in the vasculature, with levels 10-100 
fold higher than other PGs (Feletou et al., 2009; Gluais et al., 2005; Gluais et al., 2006; 
Heymes et al., 2000; Wu et al., 2005). PGI2 interacts with the prostacyclin receptor (IP) 
located on smooth muscle cells and platelets, activating vascular relaxation and 
inhibiting platelet aggregation via increases in cAMP level (Coleman et al., 1994; 
Moncada et al., 1979; Needleman et al., 1986). Normally, PGI2 is a potent vasodilator 
and a powerful endogenous inhibitor of platelet aggregation. At very high 
concentrations, however, PGI2 interacts with the TXA2 receptor (TP); this cross-
activation induces vasoconstriction (Gluais et al., 2006; Nakahata, 2008). 
 
1.1.2.2.1.3. Thromboxane (TXA2) 
TXA2 has opposing effects to PGI2, it is a very potent vasoconstrictor (even more so 
than angiotensin II) and also induces platelet aggregation (Nakahata, 2008). It causes 
platelets to change shape and aggregate together promoting thrombus formation and 
thrombosis (Ally et al., 1980). It was once thought to be mainly produced by platelets, 
but has been shown in more recent studies to also be produced (at much lower levels 
than PGI2) in the endothelium and vascular smooth muscle by thromboxane synthase 
(TXS). The biosynthesis of TXA2 is much lower in these tissues due to the lower 
expression of TXS in comparison to PGIS. TXA2 acts at the TP receptor as the most 
potent agonist; however, other PGs also interact with TP with much lower affinities to 
produce vasoconstriction (Gluais et al., 2005; Gluais et al., 2006).  
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1.1.2.2.1.4. Other PGs: PGE2, PGF2α, and PGD2 
PGE2 has diverse effects depending on tissue type and which receptor subtype is 
expressed. PGE2 is the most abundant prostaglandin in the human body, yet due to the 
limited expression of its terminal synthase in vascular smooth muscle, the contribution 
of PGE2 in endothelium-dependent vascular function is much less than PGI2 or TXA2 
(Tang et al., 2008). There are four prostaglandin E2 receptors (EP) (Sugimoto et al., 
2007), two of which cause vasodilation (EP2, EP4) via increases in cyclic adenosine 
monophosphate (cAMP), while the other two (EP1, EP3) cause vasoconstriction via 
increases in calcium mobilization/release and inhibition of cAMP (Alfranca et al., 2006; 
Coleman et al., 1994). 
 
PGF2α levels in the endothelium are much lower than PGI2 due to the low levels of its 
terminal synthase PGFS (Gluais et al., 2005; Gluais et al., 2006; Tang et al., 2008). 
PGF2α interacts with its receptor (FP) expressed in the endothelium and vascular smooth 
muscle cells (Lake et al., 1994) and can also interact with the TP receptor (Gluais et al., 
2005) to cause vasoconstriction. 
 
The levels of PGD2 tend to be very low in most vascular beds due to the very low levels 
of its terminal synthase PGDS. PGD2 has similar albeit less potent actions to PGI2. It 
inhibits platelet aggregation, increases cAMP levels and causes peripheral 
vasorelaxation (Walch et al., 1999; Whittle et al., 1978). Unlike PGI2, PGD2 can also 
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cause pulmonary vasoconstriction and bronchoconstriction (Johnston et al., 1995; 
Wasserman et al., 1980). 
 
1.1.2.2.2 Lipoxygenase pathway 
The second pathway of AA metabolism is via the lipoxygenase (LO) pathway.  AA is 
metabolized by various oxidation reactions by several specific lipoxygenases 
(5,8,9,11,12, or 15-lipoxygenase) to hydroperoxyeicosatetraenoic acid (HPETE).  Next 
HPETEs spontaneously hydrolyse to hydroxyeicosatetraenoic acids (HETEs) or 
leukotrienes (LT) (Borgeat et al., 1979; Holtzman, 1991).  For example the 5-LO 
pathway converts AA to 5-HPETE which is spontaneously hydrolysesd to 5-HETE or 
LTA2. In humans, the role of the 5-LO pathway in bronchoconstriction and 
inflammation has been well studied. Current medications for asthma include 5-LO 
inhibitors and leukotriene receptor antagonists (Drazen, 1999). 
  
1.1.2.2.3. Cytochrome P450 pathway 
The third pathway of AA metabolism is via the cytochrome P450 (CYP) pathway. The 
major products of CYP-catalyzed AA metabolism are epoxyeicosatrienoic acids (EETs) 
and ω-hydroxyeicosatrienoic acid (HETEs) (Capdevila et al., 2000). Metabolism of AA 
by CYP2J and CYP2C produces EETs (Zeldin, 2001). Soluble epoxide hydrolase (sEH) 
then catalyzes the hydrolysis of EETs to dihydroxyeicosatrienoic acids (DHETs) 
(Zeldin, 2001). In vascular smooth muscle cells, 20-HETE is the major product of CYP-
catalyzed AA metabolism of CYP4A and CYP4F (Capdevila et al., 2000). Eicosanoids 
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are produced in a cell and tissue specific manner. They exert effects on many biological 
functions as secondary messengers including regulation of vascular tone, ion transport, 
blood pressure, and control of cellular proliferation, inflammation and hemostasis (Maier 
et al., 2001; Roman et al., 2000; Zeldin, 2001). EETs and DHETs are potent 
vasodilators, while, 20-HETE is a potent vasoconstrictor. CYP-derived eicosanoids 
actions are generally mediated via large conductance Ca
2+
-activated K
+
 channels (BKCa). 
EETs have potent effects on vascular tone in numerous tissue beds including: coronary, 
cerebral, mesenteric, renal, pulmonary, and peripheral circulations (Kroetz et al., 2002; 
Lu et al., 2001; Medhora et al., 2001; Zhang et al., 2001). In the coronary circulation 
EETs have been identified as a putative EDHF, relaxing vascular smooth muscle cells by 
enhancing the opening of BKCa channels (Fisslthaler et al., 1999; Pratt et al., 2001). In 
addition to their actions as an EDHF-vasodilator, EETs also are potent anti-
inflammatory agents, inhibit leukocyte adhesion to the vascular cell wall and protect 
against hypoxia-reoxygenation injury (Node et al., 1999; Zeldin et al., 2000).  
 
In summary, healthy endothelial cells respond to a number of stimuli by releasing nitric 
oxide, which, in turn, stimulates vasorelaxation, inhibits platelet aggregation and reduces 
adhesion of leukocytes. In addition to nitric oxide, the products of AA metabolism, 
especially via the COX and CYP pathways, play important roles in modulating vascular 
tone. PGs act as either vasodilators (PGI2) or vasoconstrictors (PGH2, TXA2), enhance or 
inhibit coagulation, and aid in the regulation of vascular tone and homeostasis. CYP 
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metabolites also play important roles in maintaining vascular homeostasis. EETs (and 
DHETs) cause vasodilation while 20-HETE has vasoconstrictor actions.   
 
1.1.2.3. Endothelium derived hyperpolarizing factor (EDHF) 
When nitric oxide and PGI2 are inhibited, endothelium-mediated vasorelaxation can 
persist due a third mediator, endothelium derived hyperpolarizing factor (EDHF) 
(Urakami-Harasawa et al., 1997).  EDHFs cause hyperpolarization of the vascular 
smooth muscle cells and subsequently vasorelaxation.  Although EDHF-mediated 
vasorelaxation has been reported in numerous studies, its chemical identity has not yet 
been fully elucidated. This is in part due to its variable nature and mechanisms of action 
depending on the species and tissue bed studied. However, EDHFs are known to play an 
important role in endothelium-dependent relaxation in both healthy and diseased states 
(Bauersachs et al., 1996; Nishikawa et al., 2000; Park et al., 2008). Additionally, their 
contribution to relaxation increases as vessel size decreases, and thus they are important 
in the regulation of organ blood flow, peripheral vascular resistance and blood pressure, 
particularly when production of nitric oxide is compromised. Multiple EDHFs have been 
proposed, of which substantial evidence points to two main candidates, EETs, a 
cytochrome P-450-dependent metabolite of arachidonic acid (Archer et al., 2003; 
Bellien et al., 2006; Hecker et al., 1994), as well as the reactive oxygen species, 
hydrogen peroxide (H2O2) (Yada et al., 2003). Large-conductance, calcium-dependent 
K
+
 (BKCa) channels are a common downstream effector for these potential EDHFs 
(Archer et al., 2003; Liu et al., 2011).   
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1.1.3. Endothelial dysfunction 
Endothelial dysfunction, the loss of normal endothelial regulation of vascular structure 
and function, is exhibited in many disease states including coronary heart disease, 
hypertension, diabetes, and is also associated with advancing age. Endothelial 
dysfunction occurs when endothelial cells do not function normally. This is commonly 
characterized by a loss of the ability of the endothelial cells to release nitric oxide, 
especially if this loss is coupled with an enhancement in the release of constrictor 
prostanoids. This is the first step in a series of events leading to atherosclerosis and 
numerous cardiovascular diseases. Endothelial dysfunction alters vascular health in 
multiple ways including decreased nitric oxide bioactivity, increased superoxide 
production, attenuation of endothelium-dependent dilation, increased vascular tone and 
atherogenesis (Feletou et al., 2006; Lyons, 1997; Vanhoutte, 1997; Vanhoutte, 1998; 
Vanhoutte et al., 2009). 
 
1.1.3.1. Alterations in endothelial-derived vasoactive mediators with disease 
1.1.3.1.1. Coronary artery disease 
Endothelial dysfunction is a key characteristic of cardiovascular disease (CVD). Its 
presence predicts the severity of outcome, particularly the occurrence of myocardial 
infarction and stroke (Suwaidi et al., 2000; Vanhoutte, 1997). In patients with coronary 
artery disease, treatment with aspirin (COX inhibitor) and a TP receptor antagonist 
results in improved endothelial function (Belhassen et al., 2003; Husain et al., 1998). 
Thus, suggesting that endothelium-derived prostanoids contribute to endothelial 
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dysfunction in patients with coronary artery disease. Additionally, decreased synthesis or 
increased degradation leads to a decrease in the bioavailability of nitric oxide, which is a 
key manifestation of endothelial dysfunction that contributes to the pathogenesis of 
atherosclerosis (Vita, 2011).  
 
1.1.3.1.2. Aging 
Endothelial dysfunction increases in men after age 40 and in women after age 55 
(Celermajer et al., 1994). While the exact causes of age-dependent decreases in 
endothelial function are unknown, aging is usually associated with a reduction in the 
ability of the endothelium to elicit endothelium-dependent vasodilation in both animals 
and humans (Csiszar et al., 2002; Taddei et al., 2001; Tschudi et al., 1996). This loss of 
function occurs via numerous mechanisms related to nitric oxide-mediated dilation 
including: increased activity of arginase, augmented production of oxygen derived free 
radicals, reduced expression of eNOS, lower eNOS activity, reduced expression of 
soluble guanylyl cyclase, and decreased nitric oxide release (Csiszar et al., 2002; Kloss 
et al., 2000; Taddei et al., 2001; Tschudi et al., 1996). In addition, an enhancement of 
vasoconstrictor prostanoids potentiates age-dependent endothelial dysfunction. With 
advancing age, both COX-1 and COX-2 expression are upregulated by oxidative stress. 
In addition, PGI2 receptor (IP) expression decreases with age (Ge et al., 1995; 
Numaguchi et al., 1999; Shi et al., 2008; Tang et al., 2008). There is indirect evidence 
suggesting that untransformed PGH2 is also augmented with aging due to COX-1 and/or 
COX-2 upregulation (Dai et al., 1992; Hynes et al., 1987; Lin et al., 1994; Pagano et al., 
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1991). Numerous studies have shown increases in TXA2 and TXS mRNA in aorta and 
mesenteric arteries with age (Matz et al., 2000; Tang et al., 2008). Thus, the balance of 
dilator to constrictor prostanoids is altered with age, involving decreased sensitivity to 
PGI2 and enhanced production of constrictor prostanoids PGH2 and TXA2, which 
eventually leads to endothelial dysfunction. 
 
1.2. Therapeutic interventions 
Numerous therapeutic interventions, including antioxidants, lipid-lowering drugs, 
exercise, and hormone replacement therapy, serve to improve both coronary and 
peripheral endothelial function. Some interventions aim to improve endothelial 
dysfunction by targeting one or more of the numerous risk factors that can cause 
endothelial damage: hypertension (angiotensin-converting enzyme inhibitors and 
calcium antagonists), hypercholesterolemia (lipid-lowering agents), cigarette smoking 
(cessation), sedentary lifestyle (increased physical activity), menopause (estrogen 
replacement therapy), and diabetes mellitus (control of associated metabolic 
abnormalities). Yet others provide beneficial changes to the endothelium by promoting 
vasorelaxation, inhibiting vasoconstriction, and reducing the production of free radicals 
(Cooke, 1997). 
 
1.3. Dissertation scope 
The endothelium plays an important regulatory role in maintaining vascular homeostasis. 
The progression from a healthy functional endothelium to a dysfunctional endothelium 
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underlies the development of numerous cardiovascular diseases. The restoration of 
endothelial function to a healthy state using therapeutic interventions is a major area of 
clinical interest. Thus, the goal of this dissertation research was to investigate the role 
of two therapeutic interventions (exercise training and hormone replacement therapy) 
on two states of endothelial dysfunction (chronic coronary occlusion and aging).  
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2. PROJECT RATIONALE 
 
2.1. Project 1- chronic coronary occlusion/exercise training 
The first project utilized a model of chronic coronary artery occlusion to evaluate the 
effects of exercise training on cellular and molecular adaptations of the nonoccluded 
control and collateral-dependent vasculature. 
 
2.1.1. Coronary artery disease 
2.1.1.1. Epidemiology 
Coronary artery disease is not only the most common type of heart disease, it is also one 
of the most common causes of death worldwide claiming over 400,000 lives in 2009 (Go 
et al., 2013). That same year, coronary artery disease cost over $195 billion dollars in 
direct health care services, medications, and lost productivity. It is estimated that one-
half of all middle aged men and one-third of all middle aged women in the United States 
will develop some manifestations of coronary artery disease (Lloyd-Jones et al., 1999). 
Cardiovascular diseases are the major cause of death and disability in the United States 
in every major ethnic group for both males and females, causing a higher mortality rate 
each year than the next four leading causes combined: cancer, chronic lower respiratory 
diseases, accidents and diabetes mellitus (Lloyd-Jones et al., 2010; Rosamond et al., 
2008). While the death rate for coronary vascular disease has continued to decline over 
the last decade, the burden of the disease remains high. This year alone, an estimated 
635,000 Americans will have a new coronary attack, 280,000 will have a recurrent 
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attack, and an additional 150,000 are estimated to have silent myocardial infarctions. By 
2030, 40.8% of Americans are projected to have some form of coronary vascular disease 
(Go et al., 2013). 
 
2.1.1.2. Hemodynamic significance of coronary artery stenosis on myocardial 
function 
Coronary artery disease is characterized by atherosclerosis of the coronary arteries, the 
hallmark of which is atherosclerotic plaques, which progressively narrow the coronary 
artery lumen and impair myocardial blood flow (Falk, 1982). Depending on the severity 
of the obstruction and the speed of development, this reduction of blood flow may be 
symptomatic or asymptomatic, occur at rest or during exertion, and result in a 
myocardial infarction. It is difficult to determine the hemodynamic significance of 
coronary artery stenosis because severe stenotic lesions may be bypassed and adequately 
compensated for by collateral vessels (Falk, 1982).  
 
Animal models have provided key information about the relationship between the degree 
of stenosis and its hemodynamic significance. Critical stenosis is the degree of 
obstruction at which the peripheral vascular bed is maximally dilated and any further 
increase in lesion size will cause significant decreases in blood flow and myocardial 
ischemia at rest. Numerous studies have shown that blood flow distal to stenosis remains 
normal until luminal area is extremely reduced with severe stenosis (Furuse et al., 1975; 
Gould et al., 1975; Gould et al., 1974). Blood flow is maintained by autoregulatory 
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vasodilation of the vascular bed distal to occlusion. This peripheral vasodilation 
increases the pressure drop across stenosis by lowering arterial pressure distal to the 
lesion and maintains flow at normal or near-normal levels (Gould et al., 1975; Roth, 
1976). Abundant studies in canine preparations have reported that resting myocardial 
blood flow fails to meet demand when an isolated proximal coronary stenosis reduces 
the luminal cross-sectional area by 80-95% (Furuse et al., 1975; Gould et al., 1975; 
Gould et al., 1974; Roth, 1976). 
 
2.1.1.3. Chronic coronary occlusion as a model of coronary artery disease 
The coronary collateral circulation supplies blood flow to the compromised myocardial 
regions distal to complete coronary artery occlusion. During progressive arterial 
occlusion, blood flow to the compromised myocardial region downstream of the stenosis 
is maintained via angiogenesis (growth of new collateral vessels) and arteriogenesis 
(enlargement of preexisting collateral vessels) (Buschmann et al., 2000). In humans this 
sparse collateral vessel network is often sufficient to prevent ischemia and maintain 
myocardial function at rest, however myocardial function remains compromised during 
myocardial stress such as exercise (Kolibash et al., 1982).  
 
It is important to choose the most relevant animal models for human ischemic heart 
disease. For many years the dog was used to study chronic coronary occlusion; however, 
their innate collateral circulation is very substantial and capable of providing up to 40% 
of normal blood flow to the perfusion bed during acute occlusion (Hearse, 2000; 
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Maxwell et al., 1987). Conversely, acute occlusion in pigs normally results in infarct of 
the entire compromised region due to the sparse native collateral circulation (Savage et 
al., 1981). Porcine and human coronary anatomy and physiology are very similar, 
including minimal innate coronary collateral vessels, a right-dominant coronary system 
and analogous cardiac conduction systems (Hearse, 2000; Maxwell et al., 1987). 
Consequently, pigs are an excellent model of collateral vascular development in 
response to myocardial ischemia in humans. 
 
When coronary artery occlusion progresses gradually, sufficient collateral vessel 
recruitment and growth can occur, and as a consequence when complete stenosis is 
reached there is little or no infarction of the dependent myocardium. Collateral vessels 
are able to provide adequate arterial flow to maintain myocardial integrity during resting 
conditions, but the ability to augment blood flow in response to exercise or other stress 
may be limited. The ameroid constrictor technique is commonly used to induce collateral 
vessel growth via slow progressive occlusion. An ameroid constrictor consisting of an 
inner ring of casein surrounded by a stainless steel sheath is surgically implanted around 
a coronary artery. Casein, a hygroscopic substance, slowly swells as it absorbs body 
fluid. Gradual occlusion occurs as the stainless steel sheath forces the casein to swell 
inwardly, progressively compressing the artery until complete occlusion occurs around 
14-30 days (Elzinga, 1969).  
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2.1.2. Exercise therapy 
2.1.2.1. Effect of exercise training on endothelial function in coronary artery disease 
patients 
The effect of exercise on the vascular health of patients with coronary artery disease is of 
considerable interest and the benefits of regular exercise following a cardiac event are 
quite significant. Exercise-based cardiac rehabilitation for patients with coronary artery 
disease decreases total mortality by 20% and cardiac mortality by 26% (Taylor et al., 
2004). Participation in a comprehensive cardiac exercise based rehabilitation program 
leads to a significant reduction in cardiac events and hospital readmissions and a 
significant increase in functional capacity (Ades et al., 1997; Hedback et al., 2001).  
 
The effect of exercise training on endothelial function in patients with coronary artery 
disease has been examined in numerous clinical studies. After a 12 month exercise 
regimen, exercise-trained patients showed significant improvement in myocardial 
perfusion of the ischemic region as compared to sedentary patients (Kendziorra et al., 
2005). In another study exercise-training (4 weeks, stationary bike) reduced 
acetylcholine-induced coronary artery constriction, enhanced endothelial nitric oxide 
release, and increased coronary flow reserve (Hambrecht et al., 2000). In a follow-up 
study, patients with stable coronary artery disease that were to undergo elective bypass 
surgery were assigned to a 4 week exercise training or sedentary protocol. In agreement 
with previous findings, exercise training improved agonist-mediated endothelium-
dependent vasodilatory capacity, and enhanced both phosphorylated (Ser1177) and total 
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eNOS protein levels in left internal mammary artery of patients with stable coronary 
artery disease (Hambrecht et al., 2003). A large scale clinical trial of more than 100 
patients with stable coronary artery disease compared the effects of exercise training to 
the effects of standard percutaneous coronary intervention (PCI) with stenting. Exercise 
training was associated with a higher event-free survival, increased maximal oxygen 
uptake, and lower overall treatment cost (Hambrecht et al., 2004).  
 
In summary, this series of studies in patients with coronary artery disease provides 
significant clinical evidence that exercise training improves endothelial function and 
myocardial perfusion. However, the mechanisms underlying the enhanced 
coronary/collateral vasomotor responsiveness in improving myocardial function and 
perfusion with exercise training in coronary artery disease patients have not been fully 
elucidated. 
 
2.1.2.2. Effect of exercise training on blood flow to collateral-dependent 
myocardium 
As previously stated, there are many similarities between porcine and human coronary 
circulation in terms of collateral development and persistent regional myocardial 
dysfunction under conditions of increased myocardial oxygen demand such as with 
exercise. Thus, the porcine model has been used extensively to examine adaptations in 
the collateral circulation in response to chronic coronary occlusion and exercise training. 
Bloor and colleagues conducted a series of experiments to characterize the adaptations in 
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collateral development in response to myocardial ischemia and exercise-training (Bloor 
et al., 1984; Roth et al., 1990). In the first study, radiolabeled microspheres were used to 
determine blood flow into collateral-dependent and nonoccluded myocardial regions 
(Bloor et al., 1984). Flow in the proximal left circumflex (above the occlusion) did not 
differ from the nonoccluded left anterior descending artery. Chronic occlusion 
stimulated collateral development in and around the compromised ischemic region. 
Additionally, blood flow distal to the occlusion (in the collateral-dependent region) was 
significantly increased after 5 months of exercise-training indicating enhanced collateral 
development with exercise (Bloor et al., 1984). In a follow-up study, the effects of 
exercise-training on myocardial function after chronic coronary occlusion were 
examined at rest and during moderate and severe exercise (Roth et al., 1990). In the 
sedentary group, blood flow ratios (flow in the collateral-dependent region as compared 
to flow in the normally perfused region) were significantly increased in the endocardium 
during moderate exercise. In the exercise-trained group, blood flow ratios were even 
further enhanced in the endocardium during moderate exercise, and were also 
significantly increased in the endocardium, midmyocardium and epicardium during 
severe exercise. Interestingly, regional myocardial function improved in a corresponding 
manner. Exercise training improved systolic wall thickening in the collateral-dependent 
region at both moderate and severe exercise levels as compared to the pre-exercise stress 
test. Sedentary animals also showed improvements in systolic wall thickening at 
moderate exercise levels, although these improvements were not as prominent as seen in 
the exercise-training group (Roth et al., 1990). In additional studies, exercise training 
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improved myocardial function, increased coronary collateral reserve in the collateral-
dependent region, and enlarged total cross-sectional area of the vascular bed (White et 
al., 1998; White et al., 1992). Taken together, these studies suggest that exercise training 
enhances collateral development and subsequently improves myocardial function of the 
collateral-dependent myocardial region in the presence of critical stenosis or complete 
occlusion.  
 
2.1.2.3. Effect of exercise training on coronary vascular reactivity in the collateral-
dependent myocardium 
Exercise training improves endothelium-dependent relaxation (Griffin et al., 1999) and 
adenosine-induced relaxation (Heaps et al., 2000) in epicardial arteries within the 
collateral-dependent region. Additional studies found that exercise training restored 
endothelium-dependent vasodilation in response to bradykinin in porcine arterioles 
isolated from collateral-dependent myocardium (Griffin et al., 2001). Furthermore, 
vasodilation produced by vascular endothelial growth factor (VEGF165) in these vessels 
was enhanced by exercise training, and mediated primarily by increased nitric oxide 
bioavailability (Fogarty et al., 2004). Basal myogenic tone in both collateral-dependent 
arterioles is enhanced with exercise, similar to the effect of exercise training on 
arterioles in normal hearts (Muller et al., 1993). This increase in basal tone is associated 
with augmented vasodilator influences exerted by increased nitric oxide production and 
KV channel activity (Heaps et al., 2006). 
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2.1.2.4. Effect of exercise training on nitric oxide 
Exercise training improves endothelial function of both normal and diseased arteries. 
Moderate exercise training has a beneficial effect on collateral-dependent myocardial 
perfusion in human studies (Belardinelli et al., 1998; Hambrecht et al., 2003; Hambrecht 
et al., 2000). Similarly, exercise training restores endothelium-dependent vasodilation in 
porcine arterioles isolated from collateral-dependent myocardium (Griffin et al., 1999; 
Roth et al., 1990; Xie et al., 2013). Exercise training enhances endothelium-dependent 
relaxation, endothelial nitric oxide synthase (eNOS) mRNA expression, and eNOS 
protein levels in coronary arteries and arterioles of control animals (Laughlin et al., 
2001; Sessa et al., 1994). Exercise training increases nitric oxide generation, eNOS and 
p-eNOS gene expression in animal models of disease (Graham et al., 2004; Grijalva et 
al., 2008; Heaps et al., 2006; Tanabe et al., 2003; Zhou et al., 2010) and in human 
patients with coronary artery disease (Hambrecht et al., 2003; Hambrecht et al., 2000). 
However, the cellular and molecular mechanisms responsible for improvement in nitric 
oxide bioavailability in coronary artery disease subsequent to exercise therapy have not 
been fully elucidated. 
 
A series of studies by Heaps/Parker and colleagues using the porcine ameroid occluder 
model of chronic coronary occlusion have examined the effect of exercise training on 
endothelial-mediated relaxation and the contribution of nitric oxide. Endothelium-
dependent relaxation to bradykinin and ADP was enhanced with exercise training 
(Griffin et al., 1999). These functional endothelial improvements were partially 
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attributed to increased contribution of nitric oxide with exercise training. Furthermore, 
exercise training significantly enhanced bradykinin-mediated increases in endothelial 
calcium levels, nitric oxide levels, and the distribution of eNOS/caveolin-1 ratio at the 
plasma membrane in endothelial cells of nonoccluded control and collateral-dependent 
arteries (Zhou et al., 2010). Additionally, total eNOS and phosphorylated eNOS 
(pSer1179) levels were increased significantly with exercise training. Taken together, 
these findings provide insight into exercise training-induced adaptations in cellular 
mechanisms of nitric oxide regulation that contribute to enhanced nitric oxide production 
and agonist-mediated relaxation in arteries of occluded/stenosed hearts (Griffin et al., 
1999; Griffin et al., 2001; Heaps et al., 2006; Zhou et al., 2010). 
 
2.1.2.5. Effect of exercise training on other vascular mediators 
Under normal conditions, the major relaxing factors released from the endothelium 
include nitric oxide, prostacyclin and EDHF. As discussed previously in detail, the 
relationship between physical exercise and nitric oxide has been well studied. In contrast 
to the abundant literature on the role of nitric oxide in the vascular adaptations to 
exercise, far less is known regarding the changes in other vascular mediators during 
physical exercise (Figure 3).  
 
A few studies have examined the role of PGI2 in blood flow and vascular reactivity in 
collateral-dependent vasculature. PGI2 is by far the most abundant prostaglandin 
generated in vascular endothelial cells and is a potent vasodilator of coronary arteries 
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and resistance vessels. In dogs with chronic coronary occlusion, prostaglandins 
significantly contribute to blood flow in the collateral-dependent region but not in the 
normally perfused myocardium (Altman et al., 1992). In agreement, enhanced 
contribution of vasodilator prostanoids has been reported distal to chronic coronary 
occlusion (Rapps et al., 1997). In patients with atherosclerotic coronary artery disease 
undergoing diagnostic cardiac catheterization, indomethacin significantly decreased 
coronary sinus blood flow and increased myocardial oxygen extraction (Duffy et al., 
1999; Friedman et al., 1981; Pacold et al., 1986). This vasoconstriction in response to 
cyclooxygenase blockade appears to be facilitated by the presence of disease, since there 
was no significant change in coronary hemodynamics in response to cyclooxygenase 
blockade with ketoprofen in human subjects with angiographically normal coronary 
arteries (Neri Serneri et al., 1990b), yet inhibition of prostanoids significantly enhanced 
coronary vascular resistance in patients with coronary artery disease (Neri Serneri et al., 
1990a). Taken together, these data show that, PGI2 does not appear to influence coronary 
blood flow during basal conditions in normal human subjects but may exert a vasodilator 
influence in patients with atherosclerotic coronary artery disease. The effect of exercise 
training on cyclooxygenase contribution to blood flow to compromised myocardium in 
humans or animals has not yet been fully elucidated.  
 
Several studies have suggested that a cross-talk interaction between nitric oxide and 
PGI2 exists. Nitric oxide exerts an inhibitory effect on PGI2 production in vitro (Osanai 
et al., 2001; Osanai et al., 2000). Interestingly, inhibition of prostanoids significantly 
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blunted the duration of reactive hyperemia in dogs chronically treated with LNAME but 
had no effect in control dogs (Puybasset et al., 1996). Thus, the contribution of PGI2 in 
mediating vasodilation appears to be augmented when nitric oxide bioavailability is low. 
 
 
 
Figure 3. Alterations in the mechanisms involved in endothelium-dependent relaxation with exercise 
therapy. 
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2.1.3. Aims of Project 1 
Exercise training improves nitric oxide-dependent dilation; however, the effects of 
exercise on other compensatory vasodilator pathways are unknown. Thus, it is important 
to determine to what extent the roles of other endothelial mediators besides nitric oxide, 
including PGI2 and EDHFs, are altered by exercise training. The central hypothesis to 
be tested is that:  
 
 
Exercise training will increase the contribution of multiple compensatory pathways, 
including nitric oxide, PGI2, and EDHFs, in the underlying setting of chronic 
coronary occlusion. 
 
 
This hypothesis will be tested by addressing the following specific aims: 
Specific Aim 1: Determine the effects of chronic coronary artery occlusion and exercise 
training on vascular endothelial function. 
Specific Aim 2: Determine the effects of chronic coronary artery occlusion and exercise 
training on basal and agonist-stimulated production of nitric oxide and PGI2. 
Specific Aim 3: Determine the effects of chronic coronary artery occlusion and exercise 
training on whole cell K
+
 and BKCa channel currents. 
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2.2. Project 2- aging/hormone replacement therapy 
2.2.1. Aging 
The second project utilized a model of aging to evaluate the interactive effects of age 
and hormone replacement therapy on cellular and molecular mechanisms underlying 
cerebrovascular function. 
 
2.2.1.1. Epidemiology 
Growth of the older population has increased remarkably over the last century. A decline 
in infant and child mortality has led to an increase in life expectancy from 47.3 years to 
68.2 years over the first half of the twentieth century. Additionally, in the second half of 
the twentieth century, life expectancy continued to rise due to an increase in the survival 
of middle- and old-aged populations. This decline in mortality throughout the lifespan 
has resulted in a population with an increasingly large fraction of individuals surviving 
to old age. In 1900, 4.1% (of the 76 million people in the United States) were aged 65 
and older. By 1950, this rate doubled to 8%, and further increased in 2000 such that 
12.3% of the 276 million people in the United States were over the age of 65. Similar to 
younger individuals, heart disease is the leading cause of death in individuals aged 65 
and older, followed by cancer, stroke, chronic lower respiratory tract diseases, and 
Alzheimer’s disease. In addition, quality of life declines with advancing age, with 
increased onset of arthritis and chronic joint pain, dementia, loss of vision and hearing, 
depression, and increased physical limitations (Ferrucci et al., 2008; Lutz et al., 2008). 
The dramatic increase in the proportion of elderly in the United States’ population has 
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wide-ranging impacts throughout society including increased demand for medical care 
and social services.  
 
2.2.1.2. Age-related endothelial dysfunction 
Vascular aging is associated with structural and functional changes in the extracellular 
matrix, endothelium, and vascular smooth muscle of blood vessels. Arterial stiffening 
occurs with advancing age due to increases in vessel thickness, vessel wall collagen 
content, and size or number of smooth muscle cells (Guyton et al., 1983; Moreau et al., 
1998).  
 
In the vascular endothelium, aging causes endothelial thickening and increases the 
presence of mononuclear cells (Guyton et al., 1983). Functionally, advancing age results 
in a reduction in endothelium-dependent vasodilation (Csiszar et al., 2002; Taddei et al., 
2001; Tschudi et al., 1996). Age-related alterations in vascular reactivity are due to 
changes in the equilibrium between endothelium-derived relaxing and contracting 
factors. With advancing age there is a progressive decrease in the roles of nitric oxide 
and PGI2 with an increase in oxygen-derived free radicals and COX-derived constrictor 
prostanoids. Decreases in nitric oxide-mediated dilation with age occur due to increased 
activity of arginase, augmented production of oxygen derived free radicals, reduced 
expression of eNOS, lesser eNOS activity, reduced expression of soluble guanylyl 
cyclase, and decreased nitric oxide release (Csiszar et al., 2002; Kloss et al., 2000; 
Taddei et al., 2001; Tschudi et al., 1996). In humans, aging is associated with a decrease 
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in urinary excretion of the stable metabolite of PGI2, 6-keto-prostaglandin F1α (Hornych 
et al., 1991). In addition, PGI2 receptor (IP) expression decreases with age (Numaguchi 
et al., 1999; Tang et al., 2008). In contrast, an enhancement of vasoconstrictor 
prostanoids and an increase in reactive oxygen species potentiates age-dependent 
endothelial dysfunction. With advancing age, both COX-1 and COX-2 expression are 
upregulated by oxidative stress (Ge et al., 1995; Numaguchi et al., 1999; Shi et al., 
2008; Tang et al., 2008). Indirect evidence suggests that untransformed PGH2 is also 
augmented with aging due to COX-1/COX-2 upregulation (Dai et al., 1992; Hynes et al., 
1987; Lin et al., 1994; Pagano et al., 1991). Numerous studies have shown increases in 
TXA2 and TXS mRNA in aorta and mesenteric arteries with age (Matz et al., 2000; Tang 
et al., 2008). Additionally, several studies have reported increases in the vascular 
formation of superoxide with aging (Blackwell et al., 2004; Csiszar et al., 2002). Thus, 
the balance of endothelial dilator to constrictor factors is altered with age. This involves 
decreased role of nitric oxide and PGI2, and enhanced production of constrictor 
prostanoids PGH2 and TXA2; eventually leading to endothelial dysfunction (Figure 4). 
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Figure 4. Alterations in the mechanisms involved in endothelium-dependent relaxation with 
advancing age. 
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in both the periphery and the brain, is responsible for the local conversion of circulating 
androgens to estrogens in both sexes. The greatest peripheral source of aromatase in both 
males and females is the adipose tissue. In the human brain, aromatase is found in the 
highest levels in the hypothalamus. It is found in significantly higher levels in males and 
is regulated by estradiol in both males and females. Significant but similar low levels of 
aromatase are found in both sexes in other regions of the brain including the amygdala, 
hippocampus, midbrain and cortical regions (Roselli et al., 2009). Adding additional 
complexity, besides the synthesis of estradiol from circulating gonadal and adrenal 
precursors with aromatase, the brain also possesses all of the enzymes required for the de 
novo synthesis of steroids from cholesterol (Garcia-Segura, 2008).  
 
2.2.2.2. Mechanisms of estrogen signaling in the brain 
2.2.2.2.1. Estrogen receptors 
The classic genomic effects of estrogen in the brain are mediated by nuclear estrogen 
receptors (ER). There are two known isoforms (ERα and ERβ) found widely throughout 
the brain with differing distributions. The binding of estrogen to its intracellular receptor 
causes receptor-ligand dimerization and interactions with other co-factors in the cell. 
This dimer complex can then bind directly to estrogen response elements (EREs) within 
the promoter region of specific genes to alter transcription rate (McEwen et al., 1999). 
 
ERα is widely expressed in brain regions involved in the control of reproduction 
including the hypothalamic, preoptic, and limbic structures (anteroventral periventricular 
 35 
 
nucleus (AVPV), medial preoptic nucleus (MPN), median preoptic area, bed nucleus of 
the stria terminalis (BST), lateral septum, medial amygdala, arcuate nucleus (ARC), 
periventricular nucleus of the hypothalamus, and ventromedial nucleus (VMN)). 
Estrogen can also exert actions that are not regulated by the hypothalamus/preoptic 
regions including neuroprotection, locomotor activity, mood, memory, and cognition. 
Thus, it is also expressed in areas not traditionally associated with reproduction 
specifically the olfactory regions, cerebellum, area postrema and substantia gelatinosa of 
the spinal cord. ERβ is distributed in some limbic-hypothalamic regions where ERα is 
present (BST, medial preoptic area, MPN, medial amygdala, and AVPV), and is also 
expressed in areas without ERα (diagonal band of Broca, supraoptic area, and 
paraventricular nucleus). ERβ is also widely expressed in areas not associated with 
reproduction including the hippocampus, olfactory regions, spinal cord, cerebellum, 
substantia nigra, ventral tegmental area, dorsal Raphe and locus coeruleus (Laflamme et 
al., 1998; Mitra et al., 2003; Shughrue et al., 1997; Simerly et al., 1990). This broad 
distribution of estrogen in the brain allows estrogen to regulate diverse targets and exert 
a board range of actions. Each ER isoform regulates unique sets of target genes in tissue 
and cell-specific manners due to the unique distribution of ERα and ERβ in the brain and 
the formation of homo- or heterodimers. Although circulating estrogen can enter the 
brain, its effects are determined by which of the two ER isoforms is expressed (or co-
expressed), the ratio of ERα to ERβ in a particular brain region, the presence of 
coregulator proteins, and the binding to EREs to enable gene transcription. Thus, the 
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actions of estrogen can be differentially transduced throughout the brain (Chakraborty et 
al., 2004; Gillies et al., 2010). 
 
The role of aging in the regulation of ERs is not well understood. Interestingly, using 
receptor-specific knockout animals, ERα mediates the neuroprotective effects of 
estrogen following ischemic injury (Dubal et al., 2001). Additionally, expression of ERα 
is altered by age. It is significantly increased in the olfactory bulb of older reproductively 
senescent females (Jezierski et al., 2001), and in the AVPV and VMN regions of middle 
aged and old aged female rats (Chakraborty et al., 2003). In humans, ERα expression is 
altered with age from a nuclear localization in young females to a more cytoplasmic 
localization in older females (Hestiantoro et al., 2004). More research is necessary to 
provide a better understanding of age-related changes in ER expression and their 
regulation by gonadal hormones. 
 
2.2.2.2.2. Membrane estrogen receptor signaling 
Estrogens can also initiate rapid signaling (seconds to minutes) via interactions with the 
cell membrane in many brain regions. These actions probably involve a membrane ER 
that is not a transcription factor; however, the identity of this membrane receptor has not 
been fully elucidated thus far. Although these mechanisms are commonly referred to as 
nongenomic actions in order to distinguish them from the classic mode of steroid action, 
recent findings have shown that they may also act to regulate gene transcription. 
Emerging evidence reveals that classic “nuclear” ERα and ERβ receptors, and other 
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novel receptors such as G-protein coupled ER30 (GPR30), can be localized at the cell 
membrane to initiate rapid activation of intracellular signaling pathways (Mermelstein, 
2009; Micevych et al., 2009; Raz et al., 2008; Revankar et al., 2005; Vasudevan et al., 
2008). Estrogen directly stimulates Ca
2+
 channels and intracellular Ca
2+
 stores. This 
mobilization of Ca
2+ 
activates pathways involving: Ca
2+
-CAM-dependent kinases, 
cAMP-dependent kinases, mitogen-activated protein kinases (MAPK), extracellular 
signal-related kinases (ERK), and phosphoinositide 3-kinases (PI3K) (Boulware et al., 
2005; Mermelstein, 2009; Vasudevan et al., 2008). Additionally estrogen-activated 
signaling pathways increase mitochondrial efficiency consequently leading to decreased 
free radical generation in the brain (Brinton, 2008; Chen et al., 2009). It is interesting to 
note that most cellular mechanisms of estrogen have critical roles in cell survival, 
apoptosis, function, and neurodevelopment; and thus may promote the neuroregulatory, 
neurotrophic, and neuroprotective effects of estrogen in brain physiology and 
pathophysiology (Gillies et al., 2010). 
 
2.2.2.3. Effects of estrogen on cerebrovascular reactivity and blood flow 
Cerebrovascular function including reactivity and subsequent changes in blood flow into 
a given region is affected by variations in circulating estrogen levels. Overall, estrogen 
appears to enhance cerebral blood flow (CBF). Women tend to exhibit higher levels of 
CBF than men when they are younger, but this difference becomes less significant later 
in life, around the onset of menopause (Rodriguez et al., 1988; Shaw et al., 1984). 
Additionally CBF varies throughout the menstrual cycle (Brackley et al., 1999; Diomedi 
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et al., 2001) and is altered throughout pregnancy (Brackley et al., 1998). Additionally, in 
postmenopausal women HRT also enhances CBF (Penotti et al., 1993; Slopien et al., 
2003).  
 
Chronic exposure to estrogen positively alters cerebrovascular reactivity by decreasing 
cerebral vascular tone and increasing cerebral blood flow by enhancing endothelial 
derived nitric oxide and prostacyclin pathways. Interestingly, there appear to be striking 
sex-differences in the modulation of cerebrovascular myogenic tone, with male arteries 
constricting more in response to increasing pressure compared to females (Geary et al., 
1998). Numerous studies have reported that estrogen enhances the production of and/or 
the sensitivity of cerebral arteries to vasodilatory factors (Geary et al., 2000a; Geary et 
al., 1998; Ospina et al., 2003; Ospina et al., 2002; Pelligrino et al., 2000; Skarsgard et 
al., 1997). These actions appear to be mediated primarily through changes in vascular 
endothelial mediators including nitric oxide, PGs and EDHF (Figure 5). 
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Figure 5. Alterations in the mechanisms involved in endothelium-dependent relaxation with 
estrogen. 
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protein caveolin-1 are highest in pial arteries of ovariectomized rats as compared to 
intact or ovariectomized rats receiving estrogen treatment. Furthermore, these estrogen-
mediated decreases in caveolin-1 positively correlate with increases in eNOS activity 
(Santizo et al., 2002; Sobey et al., 2004; Xu et al., 2001). CaM, a regulatory protein 
necessary for Ca
2+
 activation of eNOS, is also enhanced by estrogen in cerebral arteries 
(Sobey et al., 2004). Numerous clinical studies and animal experiments have shown that 
cerebral arteries from females and chronically estrogen-treated animals display greater 
nitric oxide-dependent dilation as compared to males or ovariectomized females (Geary 
et al., 2000a; Geary et al., 1998; Geary et al., 2000b; Pelligrino et al., 2000; Skarsgard et 
al., 1997). Interestingly, other sex steroids do not appear to modulate nitric oxide in the 
cerebrovasculature. Neither testosterone nor progestins have any effect on eNOS levels 
or nitric oxide-mediated dilation. (Geary et al., 2000b; McNeill et al., 2002). 
Testosterone increases myogenic tone by endothelium-dependent mechanisms sensitive 
to COX and/or K
+
 channel inhibition (Geary et al., 2000b). 
 
2.2.2.4.2. Prostaglandins 
Estrogen enhances endothelium-dependent dilation that is dependent on NOS (as 
mentioned above) or COX. Estrogen shifts the balance of prostanoid synthesis towards 
greater production of vasodilator prostanoids, whereas testosterone favors production of 
constrictor prostanoids (Ospina et al., 2003). In cerebral vessels, estrogen elevates both 
COX-1 and PGIS resulting in enhanced PGI2 production (Geary et al., 2000a; Ospina et 
al., 2003; Ospina et al., 2002). Interestingly, TXA2 production was also slightly but 
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significantly elevated in young animals with estrogen-treatment, possibly a reflection of 
increased COX-1 levels (Lin et al., 2002; Ospina et al., 2002).   
 
The effects of estrogen on the prostanoid pathway have been examined in a series of 
studies by Stallone and colleagues. Reactivity of the rat thoracic aorta to vasopressin is 
substantially greater in females than in males or ovariectomized females.  Importantly, 
estrogen replacement therapy of ovariectomized females restored reactivity to VP to that 
of the intact female. Selective blockade of various prostanoid pathway enzymes and/or 
receptors revealed that constitutive forms of COX-2 and thromboxane synthase (TXS) 
exist in the systemic vasculature.  Enhanced responsiveness to VP in females was 
attributed to enhanced production of the constrictor prostanoid thromboxane and 
increased expression of COX-2, TXS and the TP receptor (Li et al., 2008; Li et al., 
2005; Sellers et al., 2008).  
 
2.2.2.5. Model of hormonal aging 
There are very few animal models that properly replicate human menopause. Endocrine 
aging is a slow, continuous, multi-stage process in humans. In humans, the loss of 
ovarian follicles with menopause results in a decline in estrogen levels (Judd et al., 
1994). During perimenopause, menstrual cycles become irregular, estrogen levels 
decline and fluctuate, and follicle-stimulating hormone (FSH) levels rise. This 
eventually leads to menopause, during which humans are acyclic, FSH is continuously 
high and estrogen levels are continuously low. This process appears to be fairly unique 
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to humans and some higher primates, as nonhuman primates such as rhesus monkeys 
may continue to menstruate normally until the end of their life (Gore et al., 2004; Woller 
et al., 2002). On the other hand, rodents experience changes in their ovarian hormonal 
profile similar to those of humans. However unlike in human menopause, this decline in 
estrogen occurs in rats without corresponding changes in the ovary or ovarian follicular 
stores. Endocrine aging in the rat occurs over time in a multistep fashion. During middle 
age they develop irregular cycles characterized by a prolonged estrus phase which 
eventually leads to acyclicity and decreased fertility.  An initial acyclic stage of 
persistent estrus (chronically elevated mid-cycle estrogen levels, cornified vaginal cells) 
is followed by persistent diestrus (chronically low levels of estrogen, leukocytic vaginal 
cytology). Thus, rats are considered to be a good model of hormonal aging as they 
exhibit similar characteristics to reproductive aging in women including gradual 
cessation of spontaneous reproductive cycles and decreased fertility (Huang et al., 1975; 
LeFevre et al., 1988). 
 
In addition to studies examining the natural progression of menopause, the effects of 
estrogen replacement with surgical menopause are of importance to human medicine. 
Surgical menopause via bilateral ovariectomy, followed by treatment with estrogen or 
placebo implants, aids in further examining the role of estrogen in differing hormonal 
ages. Another model which is commonly used examine the effects of estrogen on pre- 
and postmenopausal women utilizes rats of differing age groups approximating key 
stages of hormonal aging women (Bake et al., 2004; Johnson et al., 2005; Sohrabji, 
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2005). Mature multigravid (MA) rats aged 4-6 months who are proven breeders with 
previous successful pregnancies and normal cycles are similar to pre-menopausal 
women. Post-menopausal women are modeled by reproductively senescent (RS) rats 
aged 9-15 months who are retired breeders with previous successful pregnancies and 
display acyclicity vaginal cytology confirming constant diestrus. This has been 
commonly used as model for menopause in women (Bake et al., 2004; Johnson et al., 
2005; Sohrabji, 2005). 
 
2.2.2.6. Sexual dimorphism in health and disease 
Many human diseases have sex-specific differences in prevalence, age of onset and/or 
severity (Ober et al., 2008; Patsopoulos et al., 2007). Well-recognized examples include 
cardiovascular disease (higher predominance in men until women reach menopause) 
(Choi et al., 2007), asthma (predominant in boys until girls reach puberty) (Postma, 
2007), autoimmune diseases, depression, and Alzheimer disease (higher in women 
throughout life) (Andersen et al., 1999; Gater et al., 1998; Lockshin, 2006), and 
schizophrenia, Parkinson disease and colorectal cancer (more common in men) (Aleman 
et al., 2003; Matanoski et al., 2006; Wooten et al., 2004). The aging process is 
associated with marked sexual dimorphism in the incidence of human neurological and 
vascular diseases, but the reasons for these sex differences in disease are unclear 
(Sullivan et al., 1996).  
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2.2.2.7. Beneficial/protective effects of estrogen 
As described in detail previously, estrogen plays a fundamental role in the maintenance 
of both neuronal and vascular health in women. In younger women, endogenous 
estrogens clearly exert beneficial effects on neuronal and vascular function. 
Epidemiological studies suggest that the risk of stroke is lower in premenopausal women 
(Kawas et al., 1997; Levy et al., 1988; Messerli et al., 1987). Additionally, experiments 
using animal models have described the protective effects of estrogen (Farhat et al., 
1996; Karas, 2002; Simpkins et al., 1997). An abundance of evidence from experimental 
animal studies has established that estrogen exerts beneficial or protective effects on the 
cerebrovasculature by reducing vascular reactivity and thereby increasing blood flow 
through nitric oxide- and vasodilator prostanoid-dependent mechanisms (Geary et al., 
2000a; Geary et al., 1998; McNeill et al., 1999; McNeill et al., 2002; Orshal et al., 2004; 
Osanai et al., 2000; Ospina et al., 2003; Ospina et al., 2002). Additionally, intact young 
female rats experience less brain injury following stroke than males, yet this protective 
effect is lost with the removal of estrogen via ovariectomy (Dubal et al., 1998; Lisabeth 
et al., 2012; Rusa et al., 1999). Disruption of this endocrine environment, both during 
menopause and with advancing age, contributes to dramatic increases in the incidence of 
neurodegenerative and vascular diseases, especially stroke.  
 
2.2.2.8. Deleterious/detrimental effects of estrogen 
While endogenous estrogens, or estrogen replacement therapy following surgical 
menopause, exert beneficial effects in younger females, estrogen replacement therapy 
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appears to be detrimental in older, postmenopausal females (Murphy et al., 2003; 
Rossouw et al., 2002; Wise et al., 2009). Indeed, epidemiological and experimental 
studies reveal that both age and estrogen replacement therapy increase the risk for stroke 
and the extent of brain injury following ischemic stroke in aged females (Bath et al., 
2005; Sare et al., 2008). Data from randomized large-scale clinical trials by the 
Women’s Health Initiative (WHI) indicate that oral estrogen replacement therapy 
(conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA)- 16,608 
women or CEE alone- 10,739 women) increases ischemic stroke risk by 44% and 55% 
respectively, in otherwise healthy post-menopausal women (Hendrix et al., 2006; 
Wassertheil-Smoller et al., 2003). Smaller-scale clinical trials of women with known 
vascular disease have also shown increased stroke severity with estrogen treatment. In 
the Women’s Estrogen for Stroke Trial (WEST), women in the estrogen treatment group 
(17β-estradiol 1mg tablet/day- 664 women) showed increased risk of fatal stroke and 
worse neurologic outcome from stroke after the first cerebral ischemic event (Viscoli et 
al., 2001). The Heart and Estrogen/progestin Replacement Study (HERS) reported that 
estrogen treatment (CEE/MPA- 2763 women) did not significantly increase stroke risk 
nor did it reduce the incidence of coronary or cerebrovascular events in women with 
coronary heart disease (Hulley et al., 1998). Interestingly, HERS and the subsequent 
follow-up study HERSII, reported significant increases in the risk of thromboembolic 
events including deep vein thrombosis and pulmonary embolism, in estrogen treated 
women as compared to those taking the placebo (Grady et al., 2000; Hulley et al., 2002). 
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2.2.3. Aims of Project 2 
Since the late 1900s, estrogen has been known to exert neuroprotective effects in animal 
models of cerebral ischemia or stroke. Younger premenopausal women are protected 
from ischemic stroke as compared to males; yet this protective effect is lost after 
menopause. Additionally, premenopausal women experience less damage and greater 
functional and cognitive recovery from neurologic insult than males. Because of these 
findings, as well as supporting evidence from animal studies, exposure to estrogen was 
postulated to be neuroprotective. In 2000, an estimated 10 million women were 
receiving HRT for the alleviation of menopausal symptoms. However, after just a few 
years, reports from WHI indicated that estrogen therapy significantly increased 
incidence and severity of stroke. Thus, it is important to examine why estrogen is 
beneficial and neuroprotective in young animals but not in postmenopausal women. 
Additionally, further elucidation of the mechanisms’ underlying actions of estrogen on 
cerebrovascular function with advancing age and during health and disease are of great 
importance. 
 
It is difficult to reconcile the apparent conflict in beneficial vs. deleterious effects of 
estrogen on neurological and vascular function unless the effects of age are considered. 
Although the mechanisms underlying the beneficial effects of estrogen on 
cerebrovascular function have been studied extensively, the mechanisms responsible for 
age-dependent deleterious effects of estrogen are largely unknown. This lack of 
understanding emphasizes the importance of examining cellular and molecular 
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mechanisms underlying the role of age on the deleterious effects of estrogen replacement 
therapy and endogenous estrogen in the cerebral vasculature. Thus, the central 
hypothesis of the proposed research is that: 
 
 
Age enhances the deleterious effects of estrogen on the cerebrovasculature and alters 
the role of constrictor prostanoids in modulating cerebrovascular reactivity.  
 
 
This hypothesis will be tested by addressing the following specific aims: 
Specific Aim 1: Determine the effects of age and estrogen on reactivity to 
vasoconstrictor substances important in the regulation of cerebrovascular function. 
Specific Aim 2: Determine the effects of age and estrogen on basal and agonist-
stimulated production of prostanoids PGI2 and TXA2. 
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3. EXERCISE TRAINING ENHANCES MULTIPLE MECHANISMS OF 
RELAXATION IN CORONARY ARTERIES OF ISCHEMIC HEARTS 
 
3.1. Introduction 
The endothelium plays an important role in mediating vascular tone. In response to 
mechanical stimuli (shear stress, pulsatile pressure) or vasoactive agonists (bradykinin, 
acetylcholine), endothelium-dependent relaxation occurs through the release of 
mediators such as nitric oxide and PGI2, which affect the adjacent vascular smooth 
muscle in a paracrine manner. In addition, a third endothelium-derived dilator relaxes 
vascular smooth muscle by causing hyperpolarization of the underlying smooth muscle 
cells. While a single EDHF has not been elucidated, numerous candidate mechanisms or 
pathways have been proposed.  BKCa channels are a common downstream effector for 
several of these potential EDHFs (Archer et al., 2003; Liu et al., 2011), as well as for 
nitric oxide (Mistry et al., 1998) and PGI2 (Burnette et al., 2006).  BKCa channels are 
prominent in coronary vascular smooth muscle cells and thus, small changes in open 
probability have significant effects on membrane potential and vasomotor tone (Brayden 
et al., 1992; Ko et al., 2008).  
 
Endothelial dysfunction is characterized by impaired vasodilation, enhanced 
vasoconstriction, cell proliferation, platelet activation, vascular permeability and 
inflammation and aggregation of platelets.  In humans, all major cardiovascular risk 
factors, including hypercholesterolemia, hypertension, diabetes, and smoking, have been 
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associated with endothelial dysfunction and impaired nitric oxide bioavailability (Heitzer 
et al., 2001).  A primary feature of endothelial dysfunction is the inability of arteries and 
arterioles to dilate fully in response to vasoactive agonists (Feletou et al., 2006).   
However, other vasodilatory pathways have been shown to be augmented in conditions 
in which a reduction in nitric oxide availability exists (Bauersachs et al., 1996; Goto et 
al., 2012; Miura et al., 2001; Park et al., 2008).  This redundancy in vasodilator 
signaling pathways allows for compensation if one mechanism is impaired. 
 
The effect of exercise on the vascular health of patients with coronary artery disease is of 
considerable interest.  Moderate exercise training has been shown to markedly improve 
myocardial perfusion and cardiac contractile function in compromised myocardium of 
diseased patients (Hambrecht et al., 2003; Hambrecht et al., 2000).  Previous studies 
have shown that exercise training enhances eNOS mRNA expression in coronary arteries 
(Sessa et al., 1994) and eNOS protein levels in coronary arterioles (Laughlin et al., 
2001) of control animals. Exercise training also has been shown to increase nitric oxide 
generation, eNOS (Graham et al., 2004; Grijalva et al., 2008; Tanabe et al., 2003) and p-
eNOS (Ser1179) gene expression in animal models of disease (Heaps et al., 2006; Zhou 
et al., 2010) and in human (Ser1177) coronary artery disease patients (Hambrecht et al., 
2003).  
 
Despite evidence that exercise training restores nitric oxide-dependent relaxation in the 
coronary circulation, little is known about adaptations in other endothelium-dependent 
 50 
 
signaling pathways that may function to compensate for reduced nitric oxide 
bioavailability. In the current study, the hypothesis was that exercise training increases 
the contribution of multiple mediators to endothelium-mediated relaxation of coronary 
arteries in the underlying setting of chronic coronary artery occlusion.  Mechanistic 
adaptations in response to chronic coronary artery occlusion, as well as subsequent 
exercise training were investigated. 
 
3.2. Methods 
3.2.1. Ethical approval 
All animal protocols were in accordance with “U.S. Government Principles for the 
Utilization and Care of Vertebrate Animals Used in Testing, Research and Training” as 
detailed in the National Institutes of Health “Guide for the Care and Use of Laboratory 
Animals” and approved by the Institutional Animal Care and Use Committee at Texas 
A&M University in accordance with Association for the Assessment and Accreditation 
of Laboratory Animal Care procedures.   
 
3.2.2. Experimental animals and surgical procedures 
As described in detail previously (Heaps et al., 2000), adult female Yucatan miniature 
swine (Sinclair Research Center, Auxvasse, MO) were surgically instrumented with an 
ameroid constrictor around the proximal LCX coronary artery.  Animals were 
preanesthetized with glycopyrrolate (0.004 mg·kg
-1
 i.m.), midazolam (0.5 mg·kg
-1
 i.m.), 
and ketamine (20 mg·kg
-1
 i.m.). Surgical anesthesia was induced with 3% isoflurane. 
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Animals were intubated and anesthesia maintained with 2-3% isoflurane, balance O2 
throughout aseptic surgery. During the surgery, pigs received the following drugs as 
necessary: pancuronium or vecuronium bromide (0.1 mg·kg
-1
; neuromuscular blockers) 
and lidocaine (1 mg·kg
-1
, i.v.; antiarrythmic). Immediately following surgery, pigs 
received ketofen (3.0 mg·kg
-1
, i.v.; NSAID). Prior to surgery and during surgical 
recovery, animals received either buprenorphine hydrochloride (0.1 mg·kg
-1
, i.v.; 
analgesic) or butorphanol tartrate (0.5 mg·kg
-1
; i.v., analgesic) every 3-6 hr, as needed 
for pain relief. Antibiotics (Naxcel, 4 mg·kg
-1
, i.m.) were administered 24 hours before 
surgery, immediately prior to surgery and for two days following surgery. 
  
3.2.3. Exercise training 
Eight weeks postoperatively, pigs were randomly assigned to either sedentary (n=39) or 
exercise training (n=38) protocols, in which pigs underwent a progressive treadmill 
exercise training program 5 days/week for 14 weeks or remained confined to their pens. 
By week 12 of the progressive exercise program, animals were running 85 minutes/day, 
5 days/week, which was maintained throughout the remainder of the training regimen, as 
described in detail previously (Heaps et al., 2000).  Efficacy of the exercise training 
regimen was verified by comparison of skeletal muscle citrate synthase (oxidative 
enzyme) levels (Srere, 1969) and heart-to-body weight ratio at conclusion of the study. 
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3.2.4. Preparation of coronary arteries 
At the completion of the 14-week exercise training or sedentary protocols, pigs were 
anesthetized using rompun (2.25 mg·kg
-1
, i.m.), ketamine (35 mg·kg
-1
, i.m.) and 
pentothal sodium (30 mg·kg
-1
, i.v.), followed by administration of heparin (1000 U·kg
-1
, 
i.v.). Pigs were intubated and ventilated with room air and a left lateral thoracotomy was 
performed in the fourth intercostal space. The heart was removed and placed in iced 
Krebs bicarbonate buffer (0–4°C) and weighed. Under a dissection microscope, the LAD 
(nonoccluded) and LCX (collateral-dependent) coronary arteries were isolated and 
cleaned of myocardium and connective tissue. Visual examination of the ameroid 
occluder during dissection of the LCX artery indicated complete occlusion in all animals 
that were included in this study. Complete occlusion has also been verified previously by 
angiography (Zhou et al., 2010).  
 
3.2.5. Isometric tension studies 
Nonoccluded LAD and collateral-dependent LCX coronary arteries were cut into size-
matched rings (axial length ~3-4 mm).  Rings were mounted for isometric tension 
studies and lowered into a 20-mL vessel chamber containing Krebs buffer (in mM: 131.5 
NaCl, 5 KCl, 1.2 NaH2PO4, 1.2 MgCl2, 3.5 CaCl2, 11.2 glucose, 13.5 NaHCO3, and 
0.025 EDTA) at 37.5°C aerated with 95% O2- 5% CO2. Coronary rings were individually 
stretched to optimal length (Lmax) as determined by repeated exposure to 60 mM KCl at 
increasing lengths.  Lmax was defined as the length at which a ≥ 5% increase in length 
produced an increase in tension ≤ 10%.  Arteries were pretreated with pharmacological 
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agents indicated below for 20 min and then preconstricted with PGF2α (30 M) until 
steady state contraction was achieved.  Concentration-response relationships to 
bradykinin (10
-11
 to 10
-6
 M) or nitroprusside (10
-9 
to 10
-4
 M) were determined by 
cumulative addition in half-log increments directly into the tissue bath.  Inhibitors 
included: (1) NOS inhibitor (L-NAME, 300 μM), (2) prostanoid inhibitor (INDO, 5 
μM), and (3) BKCa channel blocker (IBTX, 100 nM). 
 
3.2.6. Endothelial cell dissociation 
Endothelial cells were enzymatically dissociated from segments of collateral-dependent 
LCX and nonoccluded LAD coronary arteries (∼1.0 mm luminal diameter). Artery 
segments were cut longitudinally and pinned lumen side up in low-Ca
2+
 (0.1 mM) 
physiological buffer  containing 294 U·mL
-1
 collagenase, 5 U·mL
-1
 elastase, 2 mg·mL
-1
 
BSA, 1 mg·mL
-1 
soybean trypsin inhibitor, and 0.4 mg·mL
-1 
DNase I in a 37 °C water 
bath for 20 min. The enzyme solution was then replaced with enzyme-free low-Ca
2+
 
solution, and isolated cells obtained by repeatedly directing a stream of low-Ca
2+
 
solution over the artery via fire-polished Pasteur pipette. Enzymatically dissociated cells 
were collected and transferred to a 15-mL conical tube. The cells were centrifuged 
(Sorvall RT7 Plus; swinging bucket rotor RTH-750; 800 rpm) for 3 min, supernatant 
was removed, and the pellet was resuspended in enzyme-free low-Ca
2+
 solution.  
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3.2.7. Detection of bradykinin-stimulated nitric oxide levels in isolated endothelial cells  
Bradykinin-stimulated nitric oxide levels were measured from freshly isolated 
endothelial cells in real-time using the fluorescent indicator, DAF-FM DA (Molecular 
Probes). Cells were incubated with DAF-FM DA (2.5 µM) for 10 min in the dark at 
room temperature, centrifuged (800 rpm) for 3 min, supernatant removed, and the pellet 
resuspended in enzyme-free low-Ca
2+
 solution. Cells were pipetted into a superfusion 
chamber and observed using an epifluorescence microscopy system, which permitted 
evaluation of DAF fluorescence from multiple user-selected endothelial cells 
simultaneously throughout the experimental protocol (NIS-Elements AR 3.0). 
Endothelial cells were morphologically distinguishable from other cell types in the 
dispersion as characterized previously (Wagner-Mann et al., 1992).  Cells were excited 
with a 175-W xenon arc lamp with a 475-nm interference filter for excitation wavelength 
(Sutter Instruments; Lambda DG-4). Fluorescence emission was captured at 530 nm 
every 15 sec and reflected to an interline transfer, progressive-scan, cooled charge-
coupled device video camera (CoolSNAP HQ; Photometrics) with a dichroic mirror. The 
microscope was equipped with an x40 oil immersion objective with a numerical 
aperature of 1.3.  After a three minute baseline period, bradykinin (10
-9
, 10
-7.5
, or 10
-6
 M) 
was superfused at five minute intervals.  To determine delta peak fluorescence, baseline 
fluorescence was subtracted from the peak fluorescence response to each bradykinin 
concentration for each cell. 
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3.2.8. Measurement of PGI2 levels 
Nonoccluded and collateral-dependent arteries were cut into rings (~1 mm axial length), 
and placed in cold Krebs (4 ˚C) on ice for 30 min. Supernatant was removed and fresh 
Krebs (± INDO or  L-NAME) was added and slowly warmed in a 37 °C water bath. 
Supernatant was once again removed and replaced with 175 μL of Krebs containing the 
following agonists/antagonists: 1) control, 2) INDO (5 µM), 3) bradykinin (10
-6
 M), 4) 
INDO (5 µM) + bradykinin (10
-6
 M), or 5) L-NAME (300 µM) + bradykinin (10
-6
 M).  
Following a 10-min incubation period at 37 °C, rings were removed from solution.  
Arterial rings and supernatant were snap-frozen in separate tubes. Supernatant samples 
were prepped in accordance with the protocol provided with the 6-keto Prostaglandin F1α 
EIA kit (Cayman Chemical, no. 515211) and diluted 1:20 immediately prior to addition 
to the 96-well plate.  BCA protein assay kit (Thermo Scientific Pierce) was used to 
determine total protein concentration of arterial rings. 
 
3.2.9. Smooth muscle cell dissociation 
All electrophysiology experiments were performed using freshly dispersed arterial 
smooth muscle cells from nonoccluded and collateral-dependent arteries.  Coronary 
arteries were pinned lumen side up in low-Ca
2+
 (0.1 mM) physiological buffer 
containing 1.4 mg/ml papain, 0.4 mg/ml DTT, 0.4 mg/ml BSA.  Cells were 
enzymatically dissociated by incubation in a 37 °C water bath for 30-45 min. The 
enzyme solution was then replaced with enzyme-free low-Ca
2+
 solution and the arteries 
dispersed with gentle trituration by micropipette for isolation of single smooth muscle 
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cells. Smooth muscle cells were morphologically distinguishable from other cell types as 
described previously (Wagner-Mann et al., 1992). Isolated cells were maintained in low-
Ca
2+ 
solution at 4 °C until use (0-6 h).  
 
3.2.10. Whole-cell voltage clamp 
K
+
 channel currents were determined using standard whole-cell voltage-clamp technique 
as used routinely by Heaps’ laboratory (Heaps et al., 2008; Heaps et al., 2005; Xie et al., 
2013). All proposed experiments were performed using freshly dispersed smooth muscle 
cells on the day of animal termination.  Cells were initially superfused with low-Ca
2+
 
PSS containing: (in mM) 138 NaCl, 5 KCl, 0.1 CaCl2, 1 MgCl2, 10 glucose, and 20 
HEPES, pH 7.4, during gigaseal formation. Heat-polished glass pipettes (2-5 MΩ) were 
filled with a solution containing (in mM): 120 KCl, 10 NaCl, 1 MgCl2, 10 EGTA, and 
10 HEPES, pH 7.1, with KOH. Ionic currents were amplified by an Axopatch 200B 
patch-clamp amplifier (Axon Instruments). Cells were continuously perfused under 
gravity flow at room temperature (22-25 °C). IBTX-sensitive currents were obtained by 
subtraction of currents in the presence of IBTX from control currents in smooth muscle 
cells isolated from nonoccluded and collateral-dependent arteries of sedentary and 
exercise-trained animals. 
 
3.2.11. Immunoblot for BKCa channel 
Arterial rings (~3 mm length; ~1.0 mm diameter) were isolated from both the collateral-
dependent LCX and nonoccluded LAD, quick frozen and stored at -80 C for later 
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immunoblot analysis, as described in detail previously (Fogarty et al., 2009). Arterial 
lysate (20 g total protein) was subjected to SDS–PAGE (4-20 % gradient gel), 
transferred
 
to PVDF membrane, and probed overnight with primary antibody.  Primary
 
antibodies included BKCa channel alpha subunit (Alomone Labs, APC-021, 1:200) and 
smooth muscle -actin (Abcam, ab21027, 1:1,000). 
 
3.2.12. Statistics 
Animal body weight, heart-to-body weight, IC50, and citrate synthase activity were 
compared between sedentary and exercise trained pigs using student’s t-test.  
Dimensional characteristics of coronary arteries, fluorescence (DAF-FM DA), PGI2, and 
immunoblot data were compared using two-way ANOVA. Bradykinin-mediated 
relaxation and whole-cell K
+
 currents were evaluated by repeated measures two-way 
ANOVA and the Greenhouse-Geisser adjustment to control for type I error due to 
unequal group sizes (Ludbrook, 1994).  If a main effect was identified by ANOVA, 
Bonferroni tests were used to detect individual differences.  A P value ≤0.05 was 
considered significant.  “n” values reflect the number of animals studied. When more 
than one coronary arterial ring from the nonoccluded or collateral-dependent region of a 
given animal was used in identical protocols, the responses from those rings were 
averaged before data analyses were conducted. 
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3.3. Results 
3.3.1. Efficacy of the exercise-training program 
Effectiveness of the 14-week exercise-training regimen was demonstrated by significant 
increases in skeletal muscle oxidative enzyme activity and an increased heart-to-body 
weight ratio in exercise-trained compared with sedentary animals.  Citrate synthase 
activity increased significantly (P ≤ 0.02 for all comparisons) in the deltoid muscle (45.6 
± 1.4 vs. 36.9 ± 1.3 μmol·min−1·g−1) and lateral (38.7 ± 1.1 vs. 32.9 ± 1.0 
μmol·min−1·g−1), medial (43.0 ± 1.8 vs. 36.3 ± 1.5 μmol·min−1·g−1), and long (34.7 ± 1.6 
vs. 29.7 ± 1.2 μmol·min−1·g−1) heads of the triceps brachii muscle in exercise-trained 
(n=38) compared with sedentary (n=39) pigs.  Although body weight did not differ 
between sedentary and exercise-trained animals at the time of death (34.42 ± 0.77 kg vs. 
33.80 ± 0.75 kg), heart-to-body weight ratio was significantly greater in exercise-trained 
compared with sedentary pigs (4.47 ± 0.10 vs. 5.27 ± 0.10; P ≤ 0.001). 
 
3.3.2. Coronary artery dimensions and characteristics 
Analyses of dimensional characteristics of arterial rings used for isometric tension 
studies revealed that the mean luminal diameter of collateral-dependent LCX rings was 
statistically smaller than nonoccluded LAD rings of sedentary pigs (Table 1).  Additional 
artery dimensions, including outer diameter, wall thickness and axial length were not 
significantly different between groups. Furthermore, the resting tension of coronary ring 
segments at Lmax was not significantly different between the four artery treatment 
groups. 
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Table 1. Dimensional characteristics of coronary arteries. 
Group n Outer 
Diameter 
(mm) 
Lumen 
Diameter 
(mm) 
Wall 
Thickness 
(mm) 
Axial 
Length 
(mm) 
RT Lmax 
Sedentary       
nonoccluded 59 1.52 ± 0.05 1.07 ± 0.04 0.21 ± 0.01 3.29 ± 0.03 1.34 ± 0.10 
collateral-
dependent 
55 1.37 ± 0.05 0.92 ± 0.04
a
  0.21 ± 0.01 3.23 ± 0.04 1.28 ± 0.11 
Exercise-trained       
nonoccluded 54 1.49 ± 0.04 1.04 ± 0.03 0.21 ± 0.01 3.25 ± 0.03 1.23 ± 0.08 
collateral-
dependent 
54 1.37 ± 0.05 0.94 ± 0.04
 
 0.20 ± 0.01 3.26 ± 0.04 1.29 ± 0.11 
Values are means ± SEM. RT Lmax, resting tension at optimal length where maximal active tension to KCl-
induced depolarization is developed. n= number of animals studied. 
a
P≤0.05 vs. sedentary nonoccluded 
 
 
3.3.3. Contribution of nitric oxide, PGI2 and BKCa channel to resting tension   
Incubation of coronary arterial rings with the NOS inhibitor, L-NAME, resulted in 
increases in resting tension that were not statistically different between treatment groups 
(Figure 6A). Combined NOS and prostanoid inhibition (L-NAME+INDO) significantly 
increased resting tension of collateral-dependent arteries of exercise-trained pigs 
compared with all other treatment groups (Figure 6B). Importantly, comparison of 
panels A and B reveals that L-NAME+ INDO attenuated the increase in resting tension 
generated by L-NAME alone in all treatment groups except collateral-dependent arteries 
of exercise-trained pigs. These data suggest that constricting rather than dilating 
prostanoids contribute to resting tone in the three other treatment groups, while 
prostanoids do not appear to contribute to basal tension in collateral-dependent arteries 
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of exercise-trained pigs. Addition of IBTX had negligible effect on resting tension 
suggesting little role of BKCa channels on basal tone. 
 
 
 
Figure 6. Effects of chronic occlusion and exercise training on the contribution of nitric oxide, 
prostanoids, and BKCa channel to resting tension. 
Increase in baseline tension in nonoccluded and collateral-dependent arteries of sedentary (SED) and 
exercise-trained (EX) pigs to L-NAME (300 μM) (A), L-NAME+INDO (5 μM) (B), and L-
NAME+INDO+IBTX (100 nM) (C). Values are means ± S.E.M. of the number of animals in parentheses. 
a
 vs. all other treatments within panel; p≤0.05. 
 
 
3.3.4. Effects of exercise training and chronic occlusion on bradykinin-mediated 
relaxation 
The effects of exercise training and chronic coronary occlusion on bradykinin-mediated 
relaxation are shown in Figure 7 and Table 2.  Comparison of control curves across 
panels revealed no significant difference in relaxation from nonoccluded and collateral-
dependent coronary arteries of either sedentary or exercise-trained animals. Concurrent 
studies were performed to determine the contribution of nitric oxide, prostanoids, and 
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BKCa channels to bradykinin-mediated relaxation.  NOS inhibition significantly 
attenuated relaxation in all groups compared with the control curve, however, relaxation 
responses remained significantly more persistent in arteries from exercise-trained 
compared with sedentary pigs.  Similarly, sensitivity (IC50, Table 2) of the arterial rings 
to bradykinin was significantly reduced following pretreatment with L-NAME, although 
the reduction in sensitivity was less pronounced in the arteries of exercise-trained pigs. 
Combined inhibition of NOS and prostanoids partially reversed the enhanced relaxation 
observed in exercise-trained pigs after NOS inhibition alone, however, significantly 
increased relaxation continued to persist in both nonoccluded and collateral-dependent 
arteries of exercise-trained animals.  Sensitivity (Table 2) of the arterial rings to 
bradykinin was not further reduced following pretreatment with L-NAME + INDO 
compared with L-NAME alone in all groups. Finally, combined blockade of NOS, 
prostanoids and BKCa channels ablated the enhanced exercise training-mediated 
relaxation in both nonoccluded and collateral-dependent arteries such that relaxation 
responses were similar across treatment groups when all three mediators were inhibited.  
Sensitivity (Table 2) of the arterial rings to bradykinin was not further reduced following 
pretreatment with L-NAME + INDO + IBTX compared with L-NAME alone or L-
NAME + INDO. 
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Figure 7. Effects of chronic occlusion and exercise training on bradykinin mediated dilation. 
Relaxation-responses of arteries from nonoccluded control or collateral-dependent, arteries of sedentary 
(A, B) or exercise trained (C, D) pigs in response to increasing concentrations of bradykinin in the absence 
and presence of inhibitors. Values are means ± S.E.M. of the number of animals in parentheses. 
a 
vs. all 
other treatment groups within panel; 
b
 vs. L-NAME curve within panel; 
c
 vs. SED curve across panels; 
p≤0.05. 
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Table 2. IC50 values (log M) for bradykinin-mediated relaxation in the absence and presence of 
inhibition of select signaling pathways. 
Group Control L-NAME L-NAME + INDO L-NAME + INDO + IBTX 
Sedentary     
nonoccluded -8.73 ± 0.09 -7.92 ± 0.14
a
 -7.72 ± 0.10
a
 -7.83 ± 0.16
a
 
collateral-
dependent 
-8.75 ± 0.11 -7.67 ± 0.30
a
 -7.62 ± 0.11
a
 -8.10 ± 0.27 
Exercise-trained     
nonoccluded -8.73 ± 0.06 -7.87 ± 0.16
a
 -7.96 ± 0.11
a
 -7.95 ± 0.17
a
 
collateral-
dependent 
-8.73 ± 0.08 -8.07 ± 0.18
a
 -7.94 ± 0.13
a
 -7.97 ± 0.10
a
 
Values are means ± SEM; n values are same as indicated in respective concentration-response curves from 
Figure 7. 
a
P≤0.05 vs. corresponding IC50 from control (no inhibitors). 
 
 
3.3.5. Smooth muscle responsiveness to nitroprusside  
The response of coronary arterial rings to the endothelium-independent nitric oxide 
donor, nitroprusside was also evaluated in this study. Concentration-dependent 
relaxation responses to nitroprusside were not significantly different in arteries from the 
collateral-dependent or nonoccluded arteries of sedentary or exercise-trained pigs (IC50 -
6.81 ± 0.08 vs. -6.58 ± 0.11 vs. -6.57 ± 0.09 vs. -6.46 ± 0.15 log M, respectively). These 
data suggest that smooth muscle responsiveness to nitric oxide was not altered by 
exercise training or chronic occlusion. 
 
3.3.6. Measurement of bradykinin-stimulated nitric oxide 
Bradykinin-mediated changes in intracellular nitric oxide levels were evaluated in 
isolated endothelial cells from both the collateral-dependent and nonoccluded arteries 
(Figure 8). There were no differences in peak delta nitric oxide levels in response to low 
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concentrations of bradykinin (10
-9 
M) across treatment groups. In contrast, higher 
concentrations of bradykinin (10
-7.5
 and 10
-6 
M) stimulated significantly enhanced nitric 
oxide levels in cells isolated from both control and collateral-dependent arteries of 
exercise-trained compared with sedentary pigs. 
 
 
 
Figure 8. Effects of chronic occlusion and exercise training on nitric oxide levels. 
Exercise training significantly enhanced nitric oxide levels in response to bradykinin (10
-7.5
 and 10
-6
 M) in 
endothelial cells isolated from both nonoccluded LAD and collateral-dependent LCX arteries compared 
with cells from sedentary pigs. Values are means ± S.E.M. number of animals, cells in parentheses. 
a 
p≤0.05 vs. respective SED value; p≤0.05. 
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3.3.7. Measurement of PGI2 
Both basal and bradykinin-stimulated changes in intracellular PGI2 levels in arterial 
rings of both the collateral-dependent LCX and nonoccluded LAD were evaluated 
(Figure 9). PGI2 levels were assessed by measurement of the stable end-product of PGI2 
metabolism, 6-keto-prostaglandin F1α. Basal PGI2 levels were not significantly altered by 
chronic occlusion or exercise training. There was no difference in PGI2 release with 
bradykinin (10
-9
 M) stimulation (data not shown) however, bradykinin (10
-6
 M) caused a 
significant increase in PGI2 levels in all arterial treatment groups. In order to examine 
the specificity of the assay, a subset of arterial rings were pretreated with the COX 
inhibitor, INDO (5 µM). Pretreatment with INDO confirmed the specificity of the assay 
and caused a significant decrease in both basal and bradykinin-stimulated PGI2 levels 
(Figure 5). To assess the possibility of cross-talk between nitric oxide and PGI2, PGI2 
levels in the presence of NOS inhibition were examined.  Interestingly, pretreatment 
with L-NAME showed a slight tendency to enhance bradykinin-stimulated PGI2 in the 
exercise-trained group, suggesting nitric oxide may hinder the exercise-trained 
enhancement of PGI2 production.  
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Figure 9. Effects of chronic occlusion and exercise training on PGI2 levels. 
Basal PGI2 was not significantly different between groups. Bradykinin caused a significant increase in 
PGI2 in all arterial groups. Treatment with indomethacin (INDO) confirmed the selectivity of the assay and 
caused a significant decrease in PGI2 both with and without bradykinin stimulation. Pretreatment with L-
NAME tended to further increase bradykinin-stimulated PGI2 in nonoccluded and collateral-dependent 
artery rings of exercise trained (EX) compared with sedentary (SED) animals. Values are means ± S.E.M. 
of the number of animals in parentheses. 
a 
vs. respective basal value; p≤0.05. 
 
 
3.3.8. Whole-cell K
+
 channel current 
The effects of chronic occlusion and exercise training on coronary smooth muscle K
+
 
channel currents are shown in Figure 10. Whole-cell currents were elicited by 500-ms 
step depolarizations to test potentials ranging from -70 to +100 mV from a holding 
potential of -80 mV. Representative traces for currents of cells from nonoccluded and 
collateral-dependent arteries of sedentary and exercise-trained pigs are shown in Figure 
10A. For current-voltage relationships in Figure 10B and C, the mean value of outward 
current for last 100 ms of each test potential normalized to cell membrane capacitance 
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(pA/pF) was plotted. Cell capacitance was not significantly different between smooth 
muscle cells from nonoccluded and collateral-dependent arteries of sedentary (11.1 ± 0.8 
and 11.7 ± 0.9 pF, respectively) and exercise trained (12.0 ± 0.8 and 12.2 ± 0.8 pF, 
respectively) pigs. Comparison of the current-voltage relationships indicated that neither 
chronic coronary occlusion nor exercise training altered whole cell K
+ 
currents in arterial 
smooth muscle cells.  
 
3.3.9. Iberiotoxin-sensitive K
+
 channel current 
The effects of chronic occlusion and exercise training on IBTX-sensitive (BKCa) channel 
currents are shown in Figure 11. IBTX-sensitive currents were obtained by subtraction 
of currents in the presence of IBTX from control currents (difference currents) (Figure 
11A). Findings from these studies revealed that BKCa channel currents were not 
significantly altered by occlusion or exercise training in coronary arterial smooth muscle 
(Figure 11B and C). 
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Figure 10. Effects of chronic occlusion and exercise training on whole-cell K+ channel current in 
coronary artery smooth muscle cells. 
Currents were elicited by 500-ms step depolarizations to potentials ranging from -70 to +100 in 10mV 
increments from a holding potential of -80mV. Representative traces for currents from cells from 
nonoccluded and collateral-dependent arteries of sedentary and exercise-trained pigs are shown (A). 
Comparison of current voltage relationships obtained by plotting the mean outward current at the end of 
each test potential normalized to cell membrane capacitance (B, C). Values are means ± S.E.M. of the 
number of animals, cells in parentheses; no significant differences existed.  
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Figure 11. Effects of chronic occlusion and exercise training on IBTX-sensitive K+ channel currents 
in coronary artery smooth muscle cells. 
Currents were obtained as described in Figure 5 legend. IBTX-sensitive K
+
 channel currents were obtained 
by subtraction of currents in the presence of IBTX (100 nM) from control currents (A). Comparison of 
IBTX-sensitive current -voltage relationships obtained by plotting the mean outward current at the end of 
each test potential normalized to cell membrane capacitance (B, C). Values are means ± S.E.M. of the 
number of animal, cells in parentheses; no significant differences existed.  
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3.3.10. BKCa channel protein 
Determination of protein by immunoblot revealed that neither occlusion nor exercise 
training significantly altered BKCa channel protein levels in coronary arteries as shown 
in Figure 12. The control protein, smooth muscle α-actin, also was not significantly 
altered by occlusion or exercise training in these arteries. 
 
 
 
Figure 12. Effects of chronic occlusion and exercise training on BKCa channel protein levels in 
coronary arteries. 
Immunoblot analyses demonstrated that BKCa channel protein levels were not significantly altered by 
occlusion or exercise training. Protein was quantified by densitometry analysis, normalized to smooth 
muscle α-actin, and expressed relative to the density of nonoccluded arteries of SED pigs. Values are 
means ± SEM of the number of animals indicated. No significant difference existed. 
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3.4. Discussion 
This study reveals the novel finding that exercise training enhances multiple mechanisms 
of endothelium-dependent vascular relaxation which appear to function in a 
compensatory manner rather than in an additive fashion. Bradykinin-stimulated nitric 
oxide levels were significantly increased after exercise training in endothelial cells of 
both nonoccluded and collateral-dependent arteries. Similarly, PGI2 levels tended to be 
increased in arteries of exercise-trained compared with respective arteries of sedentary 
pigs. Interestingly, despite increases in these signaling molecules with exercise training, 
bradykinin-mediated, endothelium-dependent relaxation was not enhanced in arteries 
from exercise-trained pigs. On the other hand, bradykinin-mediated relaxation was more 
persistent in arteries from exercise-trained pigs after inhibition of select endothelium-
dependent signaling molecules, suggesting redundancy in signaling pathways of vascular 
relaxation. 
 
While NOS inhibition significantly reduced bradykinin-mediated relaxation in all artery 
treatment groups, the effect was much more marked in arteries of sedentary compared 
with exercise-trained animals. This finding might be interpreted to indicate that the 
contribution of NOS to endothelium-mediated relaxation is significantly greater in 
sedentary compared with exercise-trained pigs or that other pathways of relaxation better 
compensate for the loss of nitric oxide in the exercise-trained animals. While combined 
inhibition of nitric oxide and prostanoids partially reversed the difference in bradykinin-
mediated relaxation in the presence of NOS inhibition alone, the significantly enhanced 
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relaxation continued to persist in arteries from exercise-trained pigs. Finally, combined 
inhibition of nitric oxide, prostanoids, and BKCa channels eliminated the persistent 
relaxation observed in arteries from exercise- trained pigs. Taken together, these data 
suggest that the contributions of nitric oxide, dilating prostanoids, and BKCa channel all 
increase after exercise training but that some limitation exists regarding the contribution 
of these molecules to the overall relaxation response, such as negative modulation 
between the mediators or their pathways. Indeed, numerous reports have revealed 
interaction of various signaling pathways that can negatively or positively regulate one 
another (Bauersachs et al., 1996; Nishikawa et al., 2000; Osanai et al., 2000; Puybasset 
et al., 1996). Previous studies have reported crosstalk between nitric oxide and PGI2 in 
the coronary circulation. In canine coronary arteries, prostanoid inhibition had no effect 
on bradykinin-mediated relaxation until combined with NOS inhibition (Puybasset et al., 
1996) and bradykinin-stimulated PGI2 release was significantly enhanced by chronic 
NOS blockade (Beverelli et al., 1997). It is noteworthy that in arteries of exercise-
trained pigs, PGI2 levels in the presence of NOS inhibition were slightly increased above 
that observed in the absence of NOS inhibition, suggesting that nitric oxide may 
negatively modulate PGI2 production. 
 
Another critical aspect of this study was quantifying nitric oxide and prostacyclin levels 
in response to bradykinin stimulation. These findings demonstrate that bradykinin-
stimulated nitric oxide levels were significantly increased in endothelial cells from 
exercise-trained compared with sedentary pigs. Taken together with the functional data 
 73 
 
in the presence of NOS inhibition, these data lend support to the interpretation that other 
pathways of relaxation better compensate after inhibition of nitric oxide in the exercise-
trained animals rather than a lesser contribution of nitric oxide production to relaxation 
in exercise-trained pigs. These results agree with previous studies from Heaps’ 
laboratory which have reported significant exercise training-induced adaptations in 
mechanisms that control nitric oxide production in both control and collateral-dependent 
coronary arteries, resulting in enhanced nitric oxide production (Zhou et al., 2010). 
Other studies have shown increased eNOS mRNA and protein levels after exercise 
training in control animals (Laughlin et al., 2001; Sessa et al., 1994) and in numerous 
animal models of disease (Graham et al., 2004; Grijalva et al., 2008; Heaps et al., 2006; 
Tanabe et al., 2003; Zhang et al., 2007). Additionally, patients with stable coronary 
artery disease that underwent an exercise training program, also exhibited improvements 
in endothelium-dependent dilation and mean peak blood flow velocity concomitant with 
increased phosphorylation of eNOS Ser1177 and total eNOS protein and mRNA 
expression in the left internal mammary artery of these patients (Hambrecht et al., 2003).  
 
Although statistical significance was not attained, PGI2 levels tended to be enhanced in 
both nonoccluded and collateral-dependent arteries of exercise-trained pigs compared to 
their respective arteries in sedentary animals. These findings coincide with the functional 
data which showed a significantly greater effect of combined NOS plus prostanoid 
inhibition compared with NOS inhibition alone in the exercise-trained but not sedentary 
pigs. Additionally, exercise-training tended to increase bradykinin-stimulated PGI2 
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levels after nitric oxide inhibition in both nonoccluded and collateral-dependent arteries. 
Taken together, this data suggest that exercise training enhances both nitric oxide and 
PGI2 contributions to vasorelaxation and that nitric oxide may have inhibitory actions on 
PGI2 production.   
 
While the effects of exercise training on nitric oxide production have been widely 
studied, exercise training-induced adaptations of PGI2-dependent responses are not well 
understood. There is debate on the importance of prostanoids in the regulation of 
coronary blood flow in humans. Studies of patients with coronary artery disease have 
shown that indomethacin diminishes vasodilation and reduces resting coronary blood 
flow (Duffy et al., 1999), suggesting that prostacyclin contributes to blood flow in 
disease states under resting conditions. In contrast, in healthy patients, prostanoids were 
not essential to basal coronary flow or to modulation of coronary flow with exercise 
(Edlund et al., 1989). Taken together, these findings suggest that blunted NOS activity 
often associated with human disease may be compensated by an increased contribution 
of prostanoids. In agreement, this study’s data clearly suggest that following NOS 
inhibition, PGI2 significantly contributes to bradykinin-mediated relaxation in coronary 
arteries of exercise-trained pigs in the underlying setting of chronic coronary artery 
occlusion. However, the role of PGI2 in the absence of NOS inhibition was not examined 
in these studies. In a canine model of permanent occlusion of the left anterior descending 
artery, resting myocardial blood flow in both the normal and collateral-dependent zones 
were not altered by cyclooxygenase blockade (Altman et al., 1995). However, during 
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exercise, indomethacin produced an increase in transcollateral resistance with was 
associated with a decrease in subendocardial flow in the collateral-dependent zone 
(Altman et al., 1995), suggesting a role of PGI2 to maintain blood flow to compromised 
regions during stress. Additionally, a single bout of exercise increases PGI2 metabolites 
in blood (Frandsen et al., 2000; Zoladz et al., 2009), and interstitial fluid of muscles 
(Frandsen et al., 2000; Karamouzis et al., 2001). Longer endurance exercise training 
programs (5-8 weeks) have also found increases in plasma concentrations (Zoladz et al., 
2010) of PGI2 in humans, however the importance of these systemic changes on local 
vascular function have not yet been determined. 
 
In this study there was no effect of chronic occlusion or exercise-training on K
+
 channel 
currents. These findings agree with previous studies which showed no effect of exercise 
training on whole-cell K
+
 currents of smooth muscle cells from coronary arteries of both 
control and hypercholesterolemic pigs (Bowles et al., 1998; Heaps et al., 2008). 
Furthermore, there was no effect of occlusion or exercise-training on BKCa channel 
currents in these studies. In contrast, the effect of IBTX in functional data suggests that 
BKCa channels do contribute to the enhanced relaxation after exercise. Taken together, 
these data suggest that a bradykinin-sensitive cellular signaling pathway that mediates 
smooth muscle relaxation via BKCa channels may be upregulated by exercise training 
and contribute to enhanced relaxation. This pathway may be a putative EDHF since the 
contribution of BKCa channels persisted in the presence of NOS and prostanoid 
inhibition. Dr. Heaps’ laboratory recently reported that exercise training significantly 
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enhances the role of the superoxide/H2O2 signaling pathway (an EDHF candidate) to 
endothelium-mediated dilation in collateral-dependent coronary arterioles (Xie et al., 
2012). EDHF and PGI2 have been suggested to act as backup vasodilators, hence their 
role in dilation may be more relevant after the nitric oxide pathway is compromised 
(Bauersachs et al., 1996; Nishikawa et al., 2000; Osanai et al., 2000). Indeed, the role of 
compensatory mechanisms has been shown to be very important in numerous vascular 
diseases associated with decreases in nitric oxide production. In hypertension, 
compensation occurs via increased K
+
 channel activity and increased release of 
hyperpolarizing factors (Asano et al., 1993) while in hypercholesterolemia 
compensatory increases in calcium-dependent potassium channels is evident (Najibi et 
al., 1994). EDHF has also been shown to compensate for diminished nitric oxide-
dependent dilation in numerous disease states including type 2 diabetes (Park et al., 
2008), hypertension (Goto et al., 2012), and hyperparathyroidism (Virdis et al., 2010).  
 
3.4.1. Clinical significance and conclusions 
Exercise training improves vascular function and contributes to enhanced myocardial 
perfusion and cardiac contractile function in numerous vascular disease states 
(Hambrecht et al., 2003; Hambrecht et al., 2000). Despite remarkable evidence for the 
therapeutic benefits of physical activity, the mechanisms by which regular exercise 
improves vascular function in the setting of coronary artery disease are not fully 
understood. The current study provides new evidence that exercise training enhances the 
contribution of numerous vasodilators, including nitric oxide, PGI2 and BKCa channels, 
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in the underlying setting of coronary artery disease. These exciting findings advance the 
current understanding of coronary vascular adaptations to exercise in health and 
coronary artery disease. 
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4. EFFECTS OF AGE AND SEX ON CEREBROVASCULAR FUNCTION IN THE 
RAT MIDDLE CEREBRAL ARTERY 
 
4.1. Introduction 
The human aging process is associated with marked sexual dimorphism in the incidences 
of neurological and vascular diseases, but the reasons for these sex differences in disease 
are unclear (Sullivan et al., 1996). Premenopausal women exhibit lower incidences of 
cardiovascular disease and stroke than males of the same age, yet after menopause these 
differences dissipate. Because the risks of cardiovascular disease and stroke increase 
with the onset of menopause, estrogen has been implicated as protective against these 
diseases. Indeed, estrogen appears to play a fundamental role in the maintenance of both 
neuronal and vascular health in younger women and to be protective against diseases 
such as coronary artery disease, hypertension, and stroke (Geary et al., 2000a; Geary et 
al., 1998; McNeill et al., 1999; Orshal et al., 2004; Ospina et al., 2003). In numerous 
animal studies, estrogen exerts beneficial effects by: 1) enhancing vasodilator factors 
including nitric oxide and prostacyclin; 2) increasing levels of endothelial nitric oxide 
synthase (eNOS), cycloxygenase-1 (COX-1) and prostacyclin synthase (PGIS) protein 
expression; and 3) stimulating the phosphatidylinositol 3-kinase/Akt pathway which 
increases eNOS phosphorylation, eNOS activity, and subsequently nitric oxide 
production (Duckles et al., 2007).  
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Disruption of the endocrine environment, both during menopause and with advancing 
age, contributes to dramatic increases in the incidence of neurodegenerative and vascular 
diseases, especially stroke. While both endogenous estrogens and estrogen replacement 
therapy following surgical menopause exert beneficial effects in younger females, 
estrogen replacement therapy appears to be detrimental in older, postmenopausal 
females. In fact, epidemiological and experimental studies revealed that both age and 
estrogen replacement therapy increase the risk for stroke and the extent of brain injury 
following ischemic stroke in aged females (Liu et al., 2009; Selvamani et al., 2010). 
Recent studies in the systemic vasculature demonstrated that estrogen enhances the 
production of and reactivity to thromboxane (TXA2) and other deleterious constrictor 
prostanoids in the female rat (Fulton et al., 2002; Li et al., 2005; Sellers et al., 2008). 
Thus, it is important to determine if age exacerbates these deleterious effects of estrogen 
involving up-regulation of vascular TXA2 production and enhancement of both 
vasoconstriction and hemostasis. 
 
It is difficult to reconcile the apparent conflict in beneficial versus deleterious effects of 
estrogen on neurological and vascular function unless the effects of age are considered. 
Although the mechanisms underlying the beneficial effects of estrogen on 
cerebrovascular function have been studied extensively, the mechanisms responsible for 
age-dependent deleterious effects of estrogen are largely unknown. Furthermore, 
research focusing on the modulation of cerebrovascular reactivity with advancing age 
and estrogen replacement is extremely limited. This lack of understanding emphasizes 
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the importance of examining the cellular and molecular mechanisms underlying the role 
of age on the deleterious effects of estrogen replacement therapy and endogenous 
estrogen on the cerebral vasculature. Thus, in the present studies, the central hypothesis 
tested is that age enhances the deleterious effects of estrogen on the cerebrovasculature 
by augmenting the role of constrictor prostanoids in cerebrovascular reactivity and tone.  
 
4.2. Methods 
4.2.1. Ethical approval 
All animal protocols were in accordance with “U.S. Government Principles for the 
Utilization and Care of Vertebrate Animals Used in Testing, Research and Training” as 
detailed in the National Institutes of Health “Guide for the Care and Use of Laboratory 
Animals” and approved by the Texas A&M University Institutional Animal Care and 
Use Committee.   
 
4.2.2. Animals and maintenance 
Neurological and vascular effects of estrogen, in both humans and experimental animals 
appear to depend upon age. Female rats of differing age groups, which approximate two 
key stages of "hormonal age" in humans, were studied. Thus, Sprague-Dawley rats of 
two different age groups were used in the present studies: mature multigravid adult (MA, 
5-6 month, pre-menopausal, estrous cyclic), and reproductively senescent (RS, 12-14 
month, post-menopausal, estrous acyclic) females (F). Age-matched male (M) rats were 
also studied as a control for the effects of aging. For the independent effects of age, it 
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was important to identify the phases of the estrous cycle in female experimental animals, 
and thus, daily vaginal smears were used to determine the stage of the estrous cycle at 
the time of experimentation. To eliminate the potential effects of cyclic surges in 
estrogen on vascular function, intact female rats were only used for experiments while in 
metestrus/diestrus phases. All rats were purchased from Harlan (Houston, TX) and 
housed at the main animal facility at Texas A&M University. Rats were housed in pairs, 
in standard plastic laboratory rat cages, in a well-ventilated room, maintained at constant 
temperature (21-26 °C), and controlled photoperiod (12 hour light: 12 hour dark). 16% 
protein global diet (soy and alfalfa-free to minimize dietary phytoestrogens, Harlan, 
Houston, TX) and water were provided ad libitum.  
 
4.2.3. Plasma estrogen concentration 
Female rats have a short estrous cycle which only lasts 4-5 days. Plasma estrogen 
concentrations oscillate markedly during the phases of the cycle, attaining a peak surge 
during proestrus and a nadir during metestrus. Because the proposed studies focus on the 
effects of estrogen levels and age, the endocrine status of all intact females was 
determined by vaginal smear. Smears were taken daily over 2-3 consecutive cycles 
immediately preceding and including the day of animal sacrifice and blood collection for 
measurement of estrogen. Estrous phase was determined by histological characteristics of 
the smears (LeFevre et al., 1988; McLean et al., 2012). Trunk blood was collected in 
EDTA coated tubes from all animals at the time of sacrifice, centrifuged, and the plasma 
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was stored at -80°C for later analysis of plasma 17β–estradiol levels by 
radioimmunoassay (RIA).  
 
4.2.4. Pressurized cannulated MCA vessel preparation 
Rats were humanely euthanized by rapid decapitation to avoid artifactual effects of 
anesthetics and minimize activation of neural and humoral pathways. The middle cerebral 
arteries (MCA) were isolated immediately and placed in chilled, Krebs-Henseleit-
bicarbonate solution (KHB). The KHB was composed of (in mM) 118.0 NaCl, 25.0 
NaHCO3, 10.0 glucose, 4.74 KCl, 2.5 CaCl2, 1.18 MgSO4, and 1.18 KH2PO4. MCAs 
from each animal were cleaned of connective and brain tissue and arterial segments were 
prepared in triplicate. They were cannulated and tied securely to the pipettes using 11-0 
ophthalmic suture.  The glass micropipettes were filled with physiological salt solution 
(PSS) with albumin which contained the following (in mM): 145 NaCl, 4.7 KCl, 2.0 
CaCl2, 1.17 MgSO4, 3.0 MOPS, 1.2 NaH2PO4, 5.0 glucose, 2.0 pyruvate, 0.02 EDTA , 
and 1% bovine serum albumin (BSA). The cannulated vessel was transferred to the stage 
of an inverted microscope (Olympus CKX41) equipped with a ×4 objective (numerical 
aperture of 0.13) and coupled with a video camera (Hitachi KP-M3AN), video monitor 
(Pelco PMM12A), DVD recorder (Phillips DVDR3475), and video micrometer (Colorado 
Video 307A). Both micropipettes were connected to a single reservoir system and were 
gradually adjusted to set the intraluminal pressure of the vessel at 85 mmHg without 
allowing flow through the vessel lumen. Leaks were detected by verifying that 
intraluminal diameter of the pressurized arteriole remained constant when the valve to the 
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reservoir system was closed. Only arterioles that were free of leaks were studied. The 
vessel chamber bath (Living Systems TC-09S) containing PSS+albumin was gradually 
warmed and maintained at 37 °C for the duration of the experiment. Luminal diameter 
was monitored continuously throughout the experiment. The vessels were allowed to 
equilibrate for 1 hour before being pretreated with pharmacological agents indicated 
below for 20 minutes. Cumulative concentration-response curves to arginine vasopressin 
(VP, 10
-12
 to 10
-7
 mol/L) were obtained by direct, cumulative additions of VP into the 
tissue baths, in the absence or presence of inhibitors including: (1) selective COX-1 
inhibitor (SC560, 1 μM); or (2) selective COX-2 inhibitor (NS398, 10 μM). Diameter 
measurements were determined in response to cumulative concentrations of VP. Percent 
constriction was determined by the following equation: % constriction = (BD – Bx)/BD 
*100, where BD is the steady-state baseline diameter after inhibitor incubation and BX is 
the diameter after each VP concentration. The concentration of VP that produced 50% of 
the maximal response (EC50) was calculated individually from the log concentration-
response curve of each MCA segment. 
 
4.2.5. Prostanoid release assay (TXA2 and PGI2) 
Vascular prostanoid production by the MCA was measured using incubation and 
radioimmunoassay methods adapted for microvessels, as described previously (Li et al., 
2008). Briefly, isolated MCA (3-4 mm axial length) were cleaned of connective tissue 
and fat, placed into chilled PSS without BSA (PSS-BSA) to rest for 60 minutes. The 
arterial segments were then transferred into 0.5 mL microcentrifuge tubes with 450 µL 
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chilled solution and gradually warmed in a water bath to 37°C for a 45 minute pre-
incubation. The pre-incubation medium was carefully aspirated and 300 µL PSS-BSA 
alone (basal) or PSS-BSA with VP 10
-9
 M (low) or PSS-BSA with VP 10
-7
 M (high) was 
added and incubated at 37°C for 45 minutes. After incubation, the incubation media were 
collected and stored at -80°C until RIA of stable metabolites of PGI2 (6-keto-
prostaglandin F1α; 6-keto-PGF1α) and TXA2 (TXB2). MCA segments were saved and 
stored at -80°C for dry weight analysis.  
 
4.2.6. Chemical reagents and drugs 
The following reagents and drugs were used: 17β-estradiol (Innovative Research of 
America; Sarasota, FL), SC560 and NS398 (Cayman Chemical; Ann Arbor MI), 
arginine VP (Bachem; Torrance, CA). All other chemicals were purchased from Sigma 
Chemical (St. Louis, MO). 
 
4.2.7. Statistics 
All data are expressed as means ± SE; n indicates the number of animals studied. One- or 
two-way analysis of variance (ANOVAs) was used to detect significant differences 
among means of all experimental groups. If a main effect was identified, pairwise 
Student’s t-tests were performed to detect significant differences between any two means 
of the data groups. Vascular function and prostanoid release data were analyzed using a 
two-way ANOVA for sex (M vs. F) and age (MA vs. RS). The effects of treatment (CTL, 
COX-1 inhibition, COX-2 inhibition) were analyzed in each experimental group using a 
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one-way ANOVA. Plasma estradiol levels, body weight and uterine weight were analyzed 
by sex and age using a two-way ANOVA and Student’s t-tests. A P value ≤ 0.05 was 
considered significant. 
 
4.3. Results 
4.3.1. Effects of age and sex on estrogen levels, body weight, and uterine weight 
Plasma 17β-estradiol concentrations, body weight and uterine weight are summarized in 
Table 3. Due to the design of the experiments, the younger MA females were in 
metestrus or diestrus phase of the estrous cycle (as determined by vaginal smears) and 
thus were sacrificed during low, non-surge, estradiol levels. Previous studies reported 
that random estradiol levels of young intact cycling females average 43.9 ± 13. (Li et al., 
2005). Uterine weights did not significantly differ with age (P > 0.05). Body weight did 
not differ with age in females; however, RS males were significantly heavier than MA 
males (P ≤ 0.01). Body weights were significantly different between males and females 
in both young MA and older RS rats (P ≤ 0.01). 
 
 
 86 
 
Table 3. Plasma 17β-estradiol concentrations, body weight and uterine weight of mature 
multigravid. 
Group Plasma Estradiol 
(pg/mL) 
Body Weight (g) Uterine Weight 
(g/100g body weight) 
 n=10-14 n=14-15 n=14 
MAF 3.24±1.38
b 
303±5.8
a
 0.41±0.04
a
 
MAM 2.55±1.06
b
 491±10.9
b
  
RSF 6.59±1.32
c
 305±9.5
a
 0.34±0.03
a
 
RSM 0.33±0.09
a
 559±12.3
c
  
Mature multigravid adult (MA, 4-6 mo.) female (F) (MAF) or age-matched male (M) rats (MAM), and 
reproductively senescent (RS, 10-12 mo.) female (F) (RSF) or age matched male rats (RSF). Values are 
means ± SE; n=no of animals studied. 
a-c 
0.0001≤P≤0.01, values within columns (estradiol, body weight, 
uterine weight) with different superscripts are significantly different.  
 
 
4.3.2. Effects of age and sex on vascular reactivity to VP 
The effects of age and sex on vasopressin-induced vasoconstriction of MCA are shown 
in Figure 13, Figure 14 and Table 4. Comparison of control curves (Figure 13) revealed 
significant age differences in both male and female at the middle VP concentration. At 
the maximal VP concentration, age had a significant effect in females but not in males, 
and in older RS rats sex also had a significant effect. In older RSF rats, VP-stimulated 
constriction was significantly decreased at both middle and maximal VP concentrations 
as compared with younger MAF. In both MA and RS male rats, VP-induced constriction 
did not differ significantly from MAF. At the middle VP concentration constrictions in 
RSM were significantly attenuated compared to MAF and MAM; however, sensitivity to 
VP did not differ.  
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Figure 13. Concentration-response curves for vasopressin (VP) in endothelium-intact pressurized 
middle cerebral artery segments prepared from MAF, MAM, RSF, and RSM. 
Mature multigravid adult (MA, 4-6 mo.) female (MAF) or age-matched male rats (MAM), and 
reproductively senescent rats (RS, 10-12 mo.) female (RSF) or age-matched male rats (RSM). Data points 
represent means ± SE (n=6 rats/group).
a-d
0.0006≤P≤0.04, mean values without common superscript differ 
significantly at middle and maximal concentrations of VP. 
 
 
In MAF, VP produced concentration-dependent constrictions with a maximal 
concentration response of 47.7% and an EC50 of 0.39 nM (Figure 14A). Both COX-1 
and COX-2 selective inhibitors, SC560 and NS398, significantly attenuated constriction 
at middle and maximal VP concentrations. Compared with the control group, maximal 
constriction was reduced by 58% and 29% by SC560 and NS398 respectively.  
 
Maximal response to VP was 32.1% in RSF with an EC50 of 0.13 nM (Figure 14C). 
Sensitivity to VP (EC50) did not differ with age in MAF vs. RSF. SC560 significantly 
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enhanced maximal constriction to VP in RSF by 39%, yet NS398 had no significant 
effect. It is important to note that the reduction in VP constriction in RSF (as compared 
to MAF, MAM and RSM) was due to an enhancement in COX-1 derived dilator 
prostanoids.  
 
In MAM, VP produced concentration-dependent constrictions with a maximal 
concentration response of 47.6% and an EC50 of 0.10 nM (Figure 14B). At the middle 
VP concentration both SC560 and NS398 attenuated constriction in MAM; however, 
these differences dissipated at the maximal VP concentration.  
 
In RSM, VP produced concentration-dependent constrictions with a maximal 
concentration response of 45.5% and an EC50 of 0.50 nM (Figure 14D). SC560 and 
NS398 had no significant effect on VP constriction in older RSM rats at either middle or 
maximal VP concentrations. 
 
 
 89 
 
 
Figure 14. Concentration-response curves for VP in endothelium-intact pressurized middle cerebral 
artery segments prepared from male and female Sprague-Dawley rats in the presence of selective 
COX inhibitors SC560 (COX-1), NS398 (COX-2), or vehicle control. 
Preparations were studied in triplicate from each animal group: mature multigravid adult (MA, 4-6 mo.) 
female (MAF) (A); or age-matched male rats (MAM) (B); reproductively senescent (RS, 10-12 mo.) 
female (RSF) (C); or age-matched male rats (RSM) (D). Data points represent means ± SE (n=6 
rats/group). 
a-f
0.0001≤P≤0.02, mean values without common superscript differ significantly at middle and 
maximal concentrations of VP. In RSM, there were no significant differences among CTL, SC560 and 
NS398 groups.  
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Table 4. Middle- and Maximal-VP concentration and EC50. 
Group Middle VP concentration  
(10
-9.5
 M, % constriction) 
Maximal VP concentration  
(10
-7
 M, % constriction) 
EC50 
(nM) 
  
Control      
MAF 26.9 ± 2.0
b 
47.7 ± 3.7
b 
0.39 ± 0.21
 a
   
MAM 30.0 ± 1.3
b 
47.6 ± 2.3
b 
0.10 ± 0.03
 a
   
RSF 19.8 ± 1.3
a 
32.1 ± 2.7
a 
0.13 ± 0.06
 a
   
RSM 22.4 ± 2.7
a 
45.5 ± 3.0
b 
0.50 ± 0.25
 a
   
SC560    
MAF 7.9 ± 1.1
a 
20.0 ± 1.6
a 
3.77 ± 2.94
 a
 
MAM 19.7 ± 4.5
b 
41.3 ± 3.1
b 
0.72 ± 0.36
 a
 
RSF 29.5 ± 2.2
c 
44.6 ± 3.7
b 
0.06 ± 0.02
 a
 
RSM 21.5 ± 3.5
b 
41.0 ± 4.6
b 
0.31 ± 0.16
 a
 
NS398    
MAF 14.6 ± 2.0
a
 33.9 ± 2.4
a 
0.81 ± 0.32
 ab
 
MAM 18.4 ± 1.3
a
 41.7 ± 3.2
b 
0.38 ± 0.10
 b
 
RSF 17.0 ± 1.5
a
 27.5 ± 1.7
a 
0.21 ± 0.07
 a
 
RSM 17.1 ± 1.9
a
 39.7 ± 2.3
b 
0.74 ± 0.24
 b
 
Mature multigravid adult (MA, 4-6 mo.) female (F) (MAF) or age-matched male (M) rats (MAM), and 
reproductively senescent (RS, 10-12 mo.) female (F) (RSF) or age matched male rats (RSF). Values are 
means ± SE; n=no of animals studied. 
a-c
0.0001≤P≤0.02, values within columns (middle VP concentration, 
maximal VP concentration, EC50) with different superscripts are significantly different.  
 
 
4.3.3. Effects of age and sex on basal and VP-stimulated PGI2 release  
Basal and VP-stimulated (low concentration 10
-9
 M; high concentration 10
-7
 M) release 
of 6-keto-PGF1α are shown in Figure 15 and Table 5. Basal and low concentration-VP 
stimulated release of 6-keto-PGF1α did not significantly differ between groups (MAF, 
MAM, RSF, or RSM) (P ≤ 0.05). Within each groups VP increased 6-keto-PGF1α 
production in a concentration-dependent manner. Low-concentration VP-stimulated 6-
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keto-PGF1α release did not differ significantly between groups. However low-VP 
increased 6-keto PGF1α by fourfold in RSF and fivefold in MAF, MAM and RSM from 
their respective basal levels. High-concentration VP increased 6-keto-PGF1α production 
eightfold in MAF, sevenfold in MAM, and sixfold in RSF and RSM from their 
respective basal levels. At high concentration VP MA females produced significantly 
more 6-keto PGF1α
 
than RS females and all other groups. 
 
 
Table 5. Basal, low- and high-VP stimulated PGI2 production. 
Group Basal  
(pg/mg/45 min) 
Low VP (10
-9) 
(pg/mg/45 min) 
High VP (10
-7
) 
(pg/mg/45 min) 
    
MAF 5,349±1,170
a
 26,207±5,245
a
 40,199±5,920
b
     
MAM 4,126±767.8
a
 18,814±4,651
a
 28,837±3,817
ab
     
RSF 3,504±752.2
a
 13,973±2,414
a
 22,302±4,611
a
     
RSM 3,985±743.1
a
 19,329±2,359
a
 24,972±2,126
ab
     
Mature multigravid adult (MA, 4-6 mo.) female (F) (MAF) or age-matched male (M) rats (MAM), and 
reproductively senescent (RS, 10-12 mo.) female (F) (RSF) or age matched male rats (RSF). Values are 
means ± SE; n=no of animals studied. 
a-c
0.0001≤P≤0.02, values within columns (Basal, low-VP, and high-
VP) with different superscripts are significantly different.  
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Figure 15. Basal and VP-stimulated (low concentration, 10
-9
 M; high concentration 10
-7
 M) release 
of 6-keto-PGF1α by middle cerebral artery segments from MAF, MAM, RSF and RSM rats. 
Mature multigravid adult (MA, 4-6 mo.) female (MAF) or age-matched male rats (MAM), and 
reproductively senescent (RS, 10-12 mo.) female (RSF) or age-matched male rats (RSM). Data points 
represent means ± SE (n=6 rats/group).
 a-c
P≤0.0001, mean values within groups (MAF, MAM, RSF, RSM) 
without common superscript are significantly different.*
, #, +
0.0001≤P≤0.02 mean values between groups 
(MAF vs. MAM vs. RSF vs. RSM) with different superscripts are significantly different. 
 
 
4.3.4. Effects of age and sex on basal and VP-stimulated TXA2 release  
Basal and vasopressin-stimulated (low concentration 10
-9
 M; or high concentration 10
-7
 
M) release of TXB2 are shown in Figure 16 and Table 6. Basal and low concentration-
VP stimulated release of TXB2 did not significantly differ between groups (MAF, 
MAM, RSF, or RSM). Within all groups VP increased TXB2 production in a 
concentration-dependent manner. Low concentration-VP increased TXB2 production 
twofold in MAF, RSF and MAM, and threefold in RSM from their respective basal 
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levels. High-VP concentration increased 6-keto-PGF1α production sixfold in MAF, 
threefold in MAM, and fourfold in RSF and RSM from their respective basal levels. At 
high concentration-VP, MAF produced significantly more TXB2 than all other groups.  
 
 
Table 6. Basal, low- and high-VP stimulated TXA2 production.  
Group Basal  
(pg/mg/45 min) 
Low VP (10
-9) 
(pg/mg/45 min) 
High VP (10
-7
) 
(pg/mg/45 min) 
    
MAF 285.7±44.6
a
 542.3±43.2
a
 1,663±118.7
b
     
MAM 338.0±38.7
a
 641.5±130.6
a
 1,063±139.0
a
     
RSF 264.9±46.7
a
 487.4±66.0
a
 1,000±110.9     
RSM 263.6±42.7
a
 692.7±87.5
a
 1,168±105.4
a
     
Mature multigravid adult (MA, 4-6 mo.) female (F) (MAF) or age-matched male (M) rats (MAM), and 
reproductively senescent (RS, 10-12 mo.) female (F) (RSF) or age matched male rats (RSF). Values are 
means ± SE; n=no of animals studied. 
a-c
0.0001≤P≤0.003, values within columns (basal, low-VP and high-
VP) with different superscripts are significantly different.  
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Figure 16. Basal and VP-stimulated (low concentration, 10
-9
 M; or high concentration 10
-7
 M) 
release of TXB2 by middle cerebral artery segments from MAF, MAM, RSF and RSM rats. 
Mature multigravid adult (MA, 4-6 mo.) female (MAF) or age-matched male rats (MAM), and 
reproductively senescent (RS, 10-12 mo.) female (RSF) or age-matched male rats (RSM). Data points 
represent means ± SE (n=6 rats/group).
 a-c
0.0001≤P≤0.003, mean values within groups (MAF, MAM, 
RSF, RSM) without common superscript are significantly different.*
, #, + 
0.0001≤P≤0.003 mean values 
between groups (MAF vs. MAM vs. RSF vs. RSM) with different superscripts are significantly different. 
 
 
 
4.4. Discussion 
The present study revealed the novel finding that age and sex alter cerebrovascular 
reactivity and prostanoid production in the MCA of Sprague-Dawley rats.  This is the 
first study to examine the effects of age and sex on the mechanisms underlying 
cerebrovascular reactivity to VP. The main findings of the study are that: 1) VP-
mediated constriction is altered by age in intact females but is unchanged in male rats,  
2) selective blockade of COX-1 or COX-2 produced age-dependent changes in 
 95 
 
cerebrovascular reactivity to VP, and 3) VP-stimulated PGI2 and TXA2 production are 
enhanced by endogenous estrogen. In intact males there were no changes in VP-induced 
vasoconstriction. Additionally, there were no significant differences in basal, low- or 
high-VP stimulated PGI2 or TXA2 production as measured by the stable metabolites 6-
keto-PGF1α or TXB2 of young MA or older RS males. In contrast, there were marked 
differences in cerebrovascular reactivity and prostanoid release with advancing age in 
females. Older intact females in this study were acyclic and thus had constant low 
endogenous estrogen levels. These older RS females exhibited reduced maximal 
constrictor responses to VP, which can be attributed to enhanced COX-1 dependent 
dilator prostanoids. VP-induced vasoconstriction in younger MA females (which were 
normally cycling) utilized both COX-1 and COX-2 constrictor prostanoids. Additionally, 
high concentration VP-stimulated PGI2 and TXA2 production were enhanced by 
endogenous estrogen and decreased with advancing age in intact female but not male 
rats. 
  
4.4.1. Effect of age on mechanisms of cerebrovascular function  
Endothelial dysfunction increases in men after age 40 and in women after age 55 
(Celermajer et al., 1994). While the exact cause of the decline in endothelial function is 
unknown, aging is usually associated with a reduction in the ability to elicit 
endothelium-dependent vasodilation in both animals and in humans (Csiszar et al., 2002; 
Taddei et al., 2001; Tschudi et al., 1996). This loss of function occurs via numerous 
mechanisms leading to attenuated nitric oxide-mediated dilation (Csiszar et al., 2002; 
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Kloss et al., 2000; Taddei et al., 2001; Tschudi et al., 1996). In addition to the age-
related changes in nitric oxide, an enhancement of vasoconstrictor prostaglandins further 
potentiates age-dependent endothelial dysfunction. With advancing age, both COX-1 
and COX-2 expression are upregulated by oxidative stress, whereas PGI2 receptor (IP) 
expression decreases (Ge et al., 1995; Numaguchi et al., 1999; Shi et al., 2008; Tang et 
al., 2008). There is also indirect evidence suggesting that untransformed PGH2 (which 
interacts with the TXA2 (TP) receptor) is also augmented with aging due to COX-
1/COX-2 upregulation (Dai et al., 1992; Hynes et al., 1987; Lin et al., 1994; Pagano et 
al., 1991). Numerous studies have reported increases in TXA2 and TXS mRNA in aorta 
and mesenteric arteries with age (Matz et al., 2000; Tang et al., 2008). Thus, in 
agreement with this study, the balance of dilator to constrictor prostanoids appears to be 
altered with age, by decreased release and/or reactivity to PGI2 and augmentation of 
constrictor prostanoid PGH2 and TXA2 production.  
 
4.4.2. Effects of sex and estrogen on mechanisms of cerebrovascular function 
Women tend to exhibit higher levels of cerebral blood flow (CBF) than men when they 
are younger but this difference becomes less significant later in life around the onset of 
menopause (Rodriguez et al., 1988; Shaw et al., 1984). Additionally CBF varies 
throughout the menstrual cycle (Brackley et al., 1999; Diomedi et al., 2001) and is 
altered during pregnancy (Brackley et al., 1998). Thus, chronic exposure to estrogen 
positively alters cerebrovascular function. Interestingly there appear to be striking sex-
differences in the modulation of cerebrovascular arterial tone, with male arteries 
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exhibiting greater myogenic tone in response to increasing pressure as compared to 
females (Geary et al., 1998). Numerous studies have reported that estrogen enhances the 
production and/or the sensitivity of cerebral arteries to vasodilatory factors nitric oxide 
and PGI2 (Geary et al., 2000a; Geary et al., 1998; Ospina et al., 2003; Ospina et al., 
2002; Pelligrino et al., 2000; Skarsgard et al., 1997). In the cerebrovasculature, estrogen 
appears to shift the prostaglandin balance towards greater production of vasodilator 
prostanoids (Ospina et al., 2003). In cerebral vessels, estrogen elevates both COX-1 and 
PGIS resulting in enhanced PGI2 production (Geary et al., 2000a; Ospina et al., 2003; 
Ospina et al., 2002) in young rats. Interestingly, TXA2 production was also slightly yet 
significantly elevated in young animals with estrogen-treatment, perhaps due to 
increased COX-1 levels (Lin et al., 2002; Ospina et al., 2002).  The age-and sex-
dependent shifts in dilator and constrictor prostanoids observed in the present study 
reveal important novel roles for the prostanoids in cerebrovascular function during 
aging. 
 
4.4.3. Divergent effects of estrogen and age on cerebrovascular function: beneficial and 
deleterious 
Earlier findings in human epidemiological (Kawas et al., 1997; Levy et al., 1988; 
Messerli et al., 1987) and experimental animal studies (Farhat et al., 1996; Karas, 2002; 
Simpkins et al., 1997) led to the belief that estrogen replacement therapy exerts 
beneficial effects on neurological and cardiovascular health and is protective against 
diseases such as dementia, coronary artery disease, hypertension, and stroke. An 
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abundance of evidence from experimental animal studies has established that estrogen 
does exert beneficial or protective effects on the cerebrovasculature by reducing vascular 
reactivity and thereby increasing blood flow through nitric oxide- and vasodilator 
prostanoid-dependent mechanisms (Geary et al., 2000a; Geary et al., 1998; McNeill et 
al., 1999; McNeill et al., 2002; Orshal et al., 2004; Osanai et al., 2000; Ospina et al., 
2003; Ospina et al., 2002). In contrast, more recent human epidemiological findings 
such as the HERS (Hulley et al., 1998), HERSII (Grady et al., 2000; Hulley et al., 
2002), and WHI studies (Hendrix et al., 2006; Wassertheil-Smoller et al., 2003) all 
suggest that in older women estrogen replacement therapy increases the incidences of 
neurological (dementia and stroke) and vascular diseases (coronary artery disease, 
hypertension, and venous thrombosis). Thus, the role of estrogen in cardiovascular 
health and disease has become controversial. Indeed, recent studies of the systemic 
vasculature have clearly established that estrogen exerts deleterious effects on the female 
vasculature through upregulation of COX-2, TXS, and TP receptor expression, thereby 
enhancing release of and responsiveness to constrictor prostanoids in the female 
systemic vasculature. Although numerous studies have examined the beneficial effects 
of estrogen replacement in numerous vascular beds of young animals (Geary et al., 
2000a; Li et al., 2008; Ospina et al., 2003), the present study is the first to examine the 
divergent effects of estrogen supplementation on cerebrovascular reactivity and 
prostanoid production in male and female rats at both younger and advanced age. 
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The results of this study provide important and novel new information on the effects of 
estrogen and advancing age on cerebrovascular function. Further understanding of the 
mechanisms by which estrogen exerts its beneficial and detrimental effects on the 
cerebrovasculature will perhaps lead to new age-and sex-specific therapeutic agents 
designed specifically to target the cerebrovasculature and other estrogen-responsive 
tissues. 
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5. EFFECTS OF AGE AND ESTROGEN ON CEREBROVASCULAR FUNCTION IN 
THE RAT MIDDLE CEREBRAL ARTERY: THE SHIFT FROM BENEFICIAL TO 
DETRIMENTAL EFFECTS 
 
5.1. Introduction 
The risk of cardiovascular diseases and stroke increases with advancing age; yet most 
research utilizes young animals. The beneficial effects of estrogen on the systemic and 
cerebral circulations are well documented in numerous animal studies; however, human 
clinical trials have reported increased incidences and severity of stroke in women 
undergoing hormone replacement therapy with estrogen. Failure to account for age-
related changes in the mechanisms that modulate vascular tone may help explain the 
paradox between the beneficial effects of estrogen observed in animal studies and the 
deleterious effects of estrogen reported in human clinical trials. Therefore, it is important 
to determine if age exacerbates the deleterious effects of estrogen on cerebrovascular 
function in female rats.  
 
Recent studies reported that age and sex alter cerebrovascular reactivity in intact 
Sprague-Dawley rats (Chapter 4). The roles of COX-1 and COX-2 derived prostanoids 
in modulating vasopressin-induced vasoconstriction of the middle cerebral artery (MCA) 
were altered with age in female but not in male rats (Chapter 4). Additionally, the 
production of prostacyclin (PGI2) and thromboxane (TXA2) by the MCA were altered 
with age in female rats (Chapter 4). Thus, in the present study the combined effects of 
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age and estrogen on the modulation of cerebrovascular function were examined in 
sexually mature and reproductively senescent female rats. The present studies tested the 
central hypothesis that age enhances the deleterious effects of exogenous estrogen on the 
cerebrovasculature by enhancing the role of constrictor prostanoids in potentiating 
female cerebrovascular reactivity. These studies appear to be the first to examine the 
combined effects of age and estrogen on the vasoconstrictor reactivity to vasopressin in 
the female cerebrovascular circulation. The aims of the present study were to determine 
the effects of age and estrogen on: 1) vascular reactivity of the female MCA to 
vasopressin, a systemic vasoconstrictor hormone important in the regulation in systemic 
and cerebrovascular function and 2) basal and agonist-stimulated production of the 
primary dilator and constrictor prostanoids, PGI2 and TXA2, respectively, that modulate 
cerebrovascular reactivity to VP in the female MCA. 
 
5.2. Methods 
5.2.1. Ethical approval 
All animal protocols were in accordance with “U.S. Government Principles for the 
Utilization and Care of Vertebrate Animals Used in Testing, Research and Training” as 
detailed in the National Institutes of Health “Guide for the Care and Use of Laboratory 
Animals” and approved by Texas A&M University Institutional Animal Care and Use 
Committee.  
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5.2.2. Animals and maintenance 
Female rats of differing age groups approximating the key stages of "hormonal age" in 
humans were studied: mature multigravid adults (MA, 5-6 month, pre-menopausal, 
estrous cyclic), and reproductively senescent adults (RS, 12-14 month, post-menopausal, 
estrous acyclic). Rats were purchased from Harlan (Houston, TX) and housed at the 
main animal facility at Texas A&M University. Rats were housed in pairs, in standard 
plastic laboratory rat cages, in a well-ventilated room, maintained at constant 
temperature (21-26 °C), with controlled photoperiod (12 hour light: 12 hour dark). 16% 
protein global diet (soy and alfalfa-free to minimize dietary phytoestrogens, Harlan, 
Houston, TX) and water were provided ad libitum.  
 
5.2.3. Ovariectomy and estrogen replacement therapy 
All female rats underwent bilateral ovariectomy (O) using standard surgical methods. 
Briefly, a dorsomedial incision through the skin was made. Subcutaneous fascia was 
cleaned and 1 cm bilateral dorsolateral incisions made in the abdominal wall to expose 
the ovarian fat pad. The ovary and uterus were carefully externalized, ligated and then 
transected. The ligated uterine horn was swabbed with Betadyne and allowed to retract 
into the abdominal cavity. The abdominal wall was closed with 4-0 vicryl absorbable 
suture and the skin incision approximated using wound clips. Prior to anesthetic 
recovery, estrogen (E) replacement therapy was initiated by subcutaneous implantation 
of three 0.05 mg 17β-estradiol 60-day time release pellets (Innovative Research, 
Sarasota, FL). Rats not receiving estrogen replacement were implanted with vehicle-
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control placebo pellets. All rats were sacrificed for in vitro experiments 14-21 days post-
surgery. 
 
5.2.4. Pressurized cannulated MCA vessel preparation 
Rats were humanely euthanized by rapid decapitation to avoid artifactual effects of 
anesthetics and minimize activation of neural and humoral pathways. The middle cerebral 
arteries (MCA) were isolated immediately and placed in chilled, Krebs-Henseleit-
bicarbonate solution (KHB). The KHB was composed of (in mM) 118.0 NaCl, 25.0 
NaHCO3, 10.0 glucose, 4.74 KCl, 2.5 CaCl2, 1.18 MgSO4, and 1.18 KH2PO4. MCAs 
from each animal were cleaned of connective and brain tissue and arterial segments were 
prepared in triplicate. They were cannulated and tied securely to the pipettes using 11-0 
ophthalmic suture.  The glass micropipettes were filled with physiological salt solution 
(PSS) with albumin which contained the following (in mM): 145 NaCl, 4.7 KCl, 2.0 
CaCl2, 1.17 MgSO4, 3.0 MOPS, 1.2 NaH2PO4, 5.0 glucose, 2.0 pyruvate, 0.02 EDTA , 
and 1% bovine serum albumin (BSA). The cannulated vessel was transferred to the stage 
of an inverted microscope (Olympus CKX41) equipped with a ×4 objective (numerical 
aperture of 0.13) and coupled with a video camera (Hitachi KP-M3AN), video monitor 
(Pelco PMM12A), DVD recorder (Phillips DVDR3475), and video micrometer (Colorado 
Video 307A). Both micropipettes were connected to a single reservoir system and were 
gradually adjusted to set the intraluminal pressure of the vessel at 85 mmHg without 
allowing flow through the vessel lumen. Leaks were detected by verifying that 
intraluminal diameter of the pressurized arteriole remained constant when the valve to the 
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reservoir system was closed. Only arterioles that were free of leaks were studied. The 
vessel chamber bath (Living Systems TC-09S) containing PSS+albumin was gradually 
warmed and maintained at 37 °C for the duration of the experiment. Luminal diameter 
was monitored continuously throughout the experiment. The vessels were allowed to 
equilibrate for 1 hour before being pretreated with pharmacological agents indicated 
below for 20 minutes. Cumulative concentration-response curves to arginine vasopressin 
(VP, 10
-12
 to 10
-7
 mol/L) were obtained by direct, cumulative additions of VP into the 
tissue baths, in the absence or presence of inhibitors including: (1) selective COX-1 
inhibitor (SC560, 1 μM); or (2) selective COX-2 inhibitor (NS398, 10 μM). Diameter 
measurements were determined in response to cumulative concentrations of VP. Percent 
constriction was determined by the following equation: % constriction = (BD – Bx)/BD 
*100, where BD is the steady-state baseline diameter after inhibitor incubation and BX is 
the diameter after each VP concentration. The concentration of VP that produced 50% of 
the maximal response (EC50) was calculated individually from the log concentration-
response curve of each MCA segment. 
 
5.2.5. Prostanoid release assay (TXA2 and PGI2) 
Vascular prostanoid production by the MCA was measured using incubation and 
radioimmunoassay methods adapted for microvessels, as described previously (Li et al., 
2008). Briefly, isolated MCA (3-4 mm axial length) were cleaned of all connective tissue 
and fat, placed into chilled PSS without BSA (PSS-BSA) to rest for 60 minutes. The 
arteries were then transferred into 0.5 mL microcentrifuge tubes with 450 µL chilled 
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solution and gradually warmed in a water bath to 37°C for a 45 minute pre-incubation. 
The pre-incubation medium was carefully aspirated and 300 µL PSS-BSA alone (basal) 
or PSS-BSA with VP 10
-9
 M (low) or PSS-BSA with VP 10
-7
 M (high) was added and 
incubated at 37°C for 45 minutes. After incubation, the incubation media were collected 
and stored at -80°C until RIA of stable metabolites of PGI2 (6-keto-prostaglandin F1α; 6-
keto-PGF1α) and TXA2 (TXB2). MCA segments were saved and stored at -80°C for dry 
weight analysis.  
 
5.2.6. Chemical reagents and drugs 
The following reagents and drugs were used: 17β-estradiol (Innovative Research of 
America; Sarasota, FL), SC560 and NS398 (Cayman Chemical; Ann Arbor MI), 
arginine VP (Bachem; Torrance, CA). All other chemicals were purchased from Sigma 
Chemical (St. Louis, MO). 
 
5.2.7. Statistics 
All data are expressed as means ± SE; n indicates the number of animals studied. One- or 
two-way analysis of variance (ANOVAs) was used to detect significant differences 
among means of all experimental groups. If a main effect was identified, pairwise 
Student’s t-tests were performed to detect significant differences between any two mean 
of the data groups. A P value ≤ 0.05 was considered significant. Vascular function and 
prostanoid release data were analyzed using a two-way ANOVA for estrogen (O vs. E) 
and age (MA vs. RS). The effects of treatment (CTL, COX-1 inhibition, COX-2 
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inhibition) were analyzed in each experimental group using a one-way ANOVA. Plasma 
estradiol levels, body weight and uterine weight were analyzed by estrogen and age using 
a two-way ANOVA and Student’s t-tests.  
 
5.3. Results 
5.3.1. Effects of age and sex on estrogen levels, body weight, and uterine weight 
Plasma 17β-estradiol concentrations, body weight and uterine weight are summarized in 
Table 7. Both younger MA and older RS females that were ovariectomized and given 
estrogen replacement had significantly lower body weights and significantly greater 
uterine weights as compared to ovariectomized females of the same age. Estradiol levels 
followed the same trends, in MAO and RSO ovariectomy decreased estradiol levels and 
estrogen replacement significantly increased estradiol levels in MAE and RSE.  
 
 
Table 7. Plasma 17β-estradiol concentrations, body weight and uterine weight of MAO, MAE, RSO 
and RSE. 
Group Estradiol  
(pg/mL) 
n=13-15 
Body Weight  
(g)
 
n=13-15 
Uterine Weight 
(g/100g body weight) 
n=12-14 
    
MAO 1.9 ± 1.3
a 
308.9 ± 12.9
b 
0.14±0.03
a     
MAE 33.6 ± 7.3
b 
259.9 ± 6.9
a 
0.24±0.02
b     
RSO 0.2 ± 0.1
a 
339.6 ± 4.1
c 
0.10±0.02
a     
RSE 37.4 ± 8.4
b 
302.8±7.0
b 
0.29±0.03
b     
Mature multigravid adult female rats (MA, 4-6 mo.), either ovariectomized (MAO) or ovariectomized and 
estrogen-replaced (MAE), and reproductively senescent female rats (RS, 10-12 mo.), either 
ovariectomized (RSO) or ovariectomized and estrogen-replaced (RSE). Values are means ± SE; n=no of 
animals studied. 
a-c
0.0001≤P≤0.04, values within columns (estradiol, body weight, uterine weight) with 
different superscripts are significantly different.  
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5.3.2. Effects of age and sex on vascular reactivity to VP 
The effects of age and sex on vasopressin-induced constriction are shown in Figure 17, 
Figure 18, and Table 8. Comparison of the concentration-response control curves in each 
of the four experimental groups (MAO, MAE, RSO, RSE) revealed significant age- and 
estrogen-dependent differences at both middle- and maximal-VP concentration (Figure 
17).  
 
In older RSO rats, VP-stimulated constriction was significantly decreased at mid-VP 
concentration and sensitivity to VP was also significantly decreased in RSO as compared 
to MAO; yet, there was no difference in max-VP concentration constriction between 
MAO and RSO.  In contrast, maximal constriction to VP was augmented significantly 
(50.6%) with estrogen in older RSE females as compared to younger MAE females. 
Estrogen attenuated constriction by 21% in younger MAE females as compared to 
ovariectomized MAO females, however, sensitivity to VP (EC50) was not altered (MAO 
vs. MAE). In contrast, estrogen augmented constriction by 27% in older RSE females as 
compared to RSO and additionally estrogen therapy significantly increased sensitivity to 
VP in older RS female.  
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Figure 17. Concentration-response curves for vasopressin (VP) in endothelium-intact pressurized 
middle cerebral artery segments prepared from MAO, MAE, RSO, and RSE. 
Mature multigravid adult female rats (MA, 4-6 mo.), either ovariectomized (MAO) or ovariectomized and 
estrogen-replaced (MAE), and reproductively senescent female rats (RS, 10-12 mo.), either 
ovariectomized (RSO) or ovariectomized and estrogen-replaced (RSE). Data points represent means ± SE 
(n=6-7 rats/group).
a-f
0.0001≤P≤0.009, mean values without common superscript differ significantly at 
middle and maximal concentrations of VP. 
 
 
In MAO, VP produced concentration-dependent constrictions with a maximal response 
of 63.6% and an EC50 of 0.14 nM. Both COX-1 and COX-2 selective inhibitors, SC560 
and NS398, significantly attenuated vasoconstriction at both middle and maximal 
concentrations of VP (Figure 18A). Compared with the control MAO group, maximal 
constriction was reduced by 14% and 16% by SC560 and NS398, respectively.  
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Maximal VP response was 59.3% in RSO with an EC50 of 0.40 nM (Figure 18C). 
Similar to MAO, in RSO, SC560 and NS398 reduced maximal-VP constriction in the 
same way, 23% and 26 % respectively.  
 
In MAE, VP produced concentration-dependent constrictions with a maximal response 
of 50.07% and an EC50 of 0.40 nM (Figure 18B). Once again both COX-1 and COX-2 
selective inhibitors, SC560 and NS398, significantly attenuated constriction at middle a 
maximal VP concentrations. Compared with the control MAE group, maximal 
constriction was reduced to a greater extent by SC560 than by NS398 (59% vs. 34%) 
indicating a greater role for COX-1 constrictor prostanoids in MAE.  
 
Maximal VP response was 75.42% in RSE with an EC50 of 0.07 nM (Figure 18D). Both 
COX-1 and COX-2 selective inhibitors, SC560 and NS398, significantly attenuated 
constriction at middle and maximal VP concentrations. However, compared with the 
control RSE group, maximal constriction was reduced to a greater extent by NS398 than 
by SC560 (65% vs. 36%) indicating a greater role for COX-2 constrictor prostanoids in 
RSE.  
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Figure 18. Concentration-response curves for VP in endothelium-intact pressurized middle cerebral 
artery segments prepared from female Sprague-Dawley rats in the presence of selective COX 
inhibitors SC560 (COX-1), NS398 (COX-2), or vehicle control. 
Vessels were prepared in triplicate from each animal group: mature multigravid adult female rats (MA, 4-6 
mo.), either ovariectomized (MAO) (A) or ovariectomized and estrogen-replaced (MAE) (B), and 
reproductively senescent female rats (RS, 10-12 mo.), either ovariectomized (RSO) (C) or ovariectomized 
and estrogen-replaced (RSE) (D). Data points represent means ± SE (n=6-7 rats/group).
a-f
P≤0.0001, mean 
values without common superscript differ significantly at middle and maximal concentrations of VP. 
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Table 8. Middle- and Maximal-VP concentration and EC50 in MAO, MAE, RSO and RSE. 
Group  
(n=6-7) 
Middle VP concentration  
(10
-9.5
 M, % constriction) 
Maximal VP concentration 
(10
-7
 M, % constriction) 
EC50 
(nM) 
  
Control      
MAO 40.2 ± 1.8
b 
63.6 ± 0.7
b 
0.14 ± 0.04
b
   
MAE 23.6 ± 1.3
a 
50.1 ± 0.9
a 
0.40 ± 0.15
bc
   
RSO 26.2 ± 1.4
a 
59.3 ± 1.1
b 
0.40 ± 0.04
c
   
RSE 52.0 ± 1.9
c 
75.4 ± 1.1
c 
0.07 ± 0.01
a
   
SC560    
MAO 29.0 ± 1.3
b 54.5 ± 1.1
c 
0.37 ± 0.07
c 
 
MAE 4.7 ± 0.5
a 
20.8 ± 0.7
a 
2.72 ± 0.41
d
 
RSO 25.7 ± 0.8
b 
45.6 ± 1.0
b 
0.21 ± 0.02
b
 
RSE 30.7 ± 1.4
b 
47.9 ± 1.0
b 
0.13 ± 0.04
a
 
NS398    
MAO 23.6 ± 0.9
b 
53.0 ± 0.8
a 
0.46 ± 0.10
a
 
MAE 13.4 ± 1.2
a 
32.8 ± 0.2
b 
0.98 ± 0.40
a
 
RSO 17.4 ± 1.1
a 
43.9 ± 1.3
b 
1.00 ± 0.26
a
 
RSE 10.7 ± 0.9
ab 
26.8 ± 1.7
a 
1.02 ± 0.42
a
 
Mature multigravid adult female rats (MA, 4-6 mo.), either ovariectomized (MAO) or ovariectomized and 
estrogen-replaced (MAE), and reproductively senescent female rats (RS, 10-12 mo.), either 
ovariectomized (RSO) or ovariectomized and estrogen-replaced (RSE). Values are means ± SE; n=no of 
animals studied. 
a-c
0.0001≤P≤0.009, values within columns (Middle VP concentration, Maximal VP 
concentration, EC50) with different superscripts are significantly different.  
 
 
5.3.3. Effects of age and sex on basal and VP-stimulated PGI2 production 
Basal and vasopressin-stimulated (low concentration 10
-9
 M; or high concentration 10
-7
 
M) release of 6-keto-PGF1α (stable metabolite of PGI2) are shown in Figure 19 and Table 
9. Basal release of 6-keto-PGF1α did not differ significantly among the experimental 
groups (MAO, MAE, RSO, or RSE). Within all groups VP increased 6-keto-PGF1α 
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production in a concentration-dependent manner. Low VP concentration increased 6-
keto-PGF1α production 3 fold in all groups. Age had no significant effect on low 
concentration VP-stimulation of 6-keto-PGF1α production in ovariectomized or estrogen 
replaced females (MAO vs. RSO and MAE vs. RSE); however, 6-keto-PGF1α production 
was significantly increased with estrogen in both ages (MAO vs. MAE and RSO vs. 
RSE). With advancing age high concentration VP-stimulated production of 6-keto-
PGF1α was significantly decreased in RSE as compared to MAE, with no differences in 
RSO vs. MAO. In contrast, high concentration VP-stimulated 6-keto-PGF1α release was 
significantly increased with estrogen in both MA and RS (MAO vs. MAE and RSO vs. 
RSE). High-VP concentration increased 6-keto-PGF1α production 6 fold in MAE and 5 
fold in MAO, RSO and RSE from their respective basal levels. At high VP concentration 
MAE produced significantly more 6-keto-PGF1α than all other groups.  
 
 
Table 9. Basal, low- and high-VP stimulated PGI2 in MAO, MAE, RSO and RSE. 
Group 
 
Basal  
(pg/mg/45 min) 
Low VP (10
-9) 
(pg/mg/45 min) 
High VP (10
-7
) 
(pg/mg/45 min) 
    
MAO 4,607 ± 427.4
a
 12,304 ± 2,136
a
 22,805 ± 3,108
a 
    
MAE 5,646 ± 786.9
a
 18,712 ± 1,913
b
 35,975 ± 2,133
c 
    
RSO 3,878 ± 744.2
a
 12,818 ± 1,603
a
 18,499 ± 1,563
a 
    
RSE 5,867 ± 998.0
a
 18,546 ± 1,183
b
 28,796 ± 2,395
b 
    
Mature multigravid adult female rats (MA, 4-6 mo.), either ovariectomized (MAO) or ovariectomized and 
estrogen-replaced (MAE), and reproductively senescent female rats (RS, 10-12 mo.), either 
ovariectomized (RSO) or ovariectomized and estrogen-replaced (RSE). Values are means ± SE; n=6 
rats/group. 
a-c
0.0001≤P≤0.02, values within columns (Basal, low VP, high VP) with different superscripts 
are significantly different.  
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Figure 19. Basal and vasopressin-stimulated (low concentration, 10
-9
 M; or high concentration 10
-7
 
M) release of 6-keto-PGF1α by middle cerebral artery segments from MAO, MAE, RSO and RSE 
rats. 
Mature multigravid adult female rats (MA, 4-6 mo.), either ovariectomized (MAO) or ovariectomized and 
estrogen-replaced (MAE), and reproductively senescent female rats (RS, 10-12 mo.), either 
ovariectomized (RSO) or ovariectomized and estrogen-replaced (RSE). Values are means ± SE; n=6 
rats/group. 
a-c
P≤0.0001, mean values within groups (MAO, MAE, RSO, RSE) without common 
superscript are significantly different.*
, #, + 
0.0001≤P≤0.02 mean values between groups (MAO vs. MAE 
vs. RSO vs. RSE) with different superscripts are significantly different.  
 
 
5.3.4. Effects of age and sex on basal and VP-stimulated TXA2 production 
Basal and vasopressin-stimulated (low concentration 10
-9
 M; high concentration 10
-7
 M) 
release of TXB2 (stable metabolite of TXA2) are shown in Figure 20 and Table 10. Basal 
release of TXB2 did not significantly differ between groups (MAO, MAE, RSO, or 
RSE). In MAO and RSO there was no difference between basal and low concentration-
VP TXB2 production; however, in MAE, estrogen replacement increased TXB2 
production 2 fold in MAE and 3 fold in RSE. Thus, TXB2 production increased in a 
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concentration-dependent manner, indicating increased sensitivity to VP with estrogen 
treatment. Age had no significant effect on low-concentration VP-stimulated TXB2 
release in ovariectomized or estrogen-treated groups (MAO vs. RSO and MAE vs. 
RSE); however, TXB2 release was significantly increased with estrogen in both younger 
and older females (MAO vs. MAE and RSO vs. RSE). TXB2 production was not 
different between MAO and RSO; however age and estrogen increased TXB2 production 
in older RSE as compared to MAE. High-concentration VP-stimulated TXB2 release was 
significantly increased with estrogen in both MA and RS (MAO vs. MAE and RSO vs. 
RSE). High-VP concentration increased TXB2 production 3 fold in MAO, 4 fold in 
MAE, 3 fold in RSO and 7 fold in RSE from their respective basal levels. At high VP 
concentration RSE produced significantly more TXB2 than all other groups.  
 
 
Table 10. Basal, low- and high-VP stimulated TXA2 in MAO, MAE, RSO and RSE. 
Group 
(n=7-8) 
Basal  
(pg/mg/45 min) 
Low VP (10
-9) 
(pg/mg/45 min) 
High VP (10
-7
) 
(pg/mg/45 min) 
    
MAO 242.8 ± 30.4
a 
325.4 ± 46.2
a 
670.9 ± 57.4
a 
    
MAE 302.8 ± 75.5
a 
618.6 ± 76.6
b 
1,085 ± 70.0
b 
    
RSO 202.6 ± 37.6
a 
262.8 ± 70.4
a 
527.1 ± 71.1
a 
    
RSE 187.1 ± 37.6
a 
468.0 ± 78.7
b 
1,397 ± 73.2
c 
    
Mature multigravid adult female rats (MA, 4-6 mo.), either ovariectomized (MAO) or ovariectomized and 
estrogen-replaced (MAE), and reproductively senescent female rats (RS, 10-12 mo.), either 
ovariectomized (RSO) or ovariectomized and estrogen-replaced (RSE). Values are means ± SE; n=6 
rats/group. 
a-c
0.0001≤P≤0.003, values within columns (Basal, low VP, high VP) with different superscripts 
are significantly different.  
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Figure 20. Basal and vasopressin-stimulated (low concentration, 10
-9
 M; or high concentration 10
-7
 
M) release of TXB2 by middle cerebral artery segments from MAO, MAE, RSO and RSE rats. 
Mature multigravid adult female rats (MA, 4-6 mo.), either ovariectomized (MAO) or ovariectomized and 
estrogen-replaced (MAE), and reproductively senescent female rats (RS, 10-12 mo.), either 
ovariectomized (RSO) or ovariectomized and estrogen-replaced (RSE). Values are means ± SE; n=6 
rats/group. 
a-c
0.0001≤P≤0.003, mean values within groups (MAO, MAE, RSO, RSE) without common 
superscript are significantly different.*
, #, + 
0.0001≤P≤0.003 mean values between groups (MAO vs. MAE 
vs. RSO vs. RSE) with different superscripts are significantly different.  
 
 
5.4. Discussion 
In the present investigation, the effects of age and exogenous estrogen on 
cerebrovascular reactivity and prostanoid production were examined in the MCA of 
ovariectomized and estrogen-replaced female Sprague-Dawley rats. The results reveal 
that estrogen is an important regulator of the vasoconstrictor responses of the MCA to 
VP in the female rat and that it exerts opposing effects on cerebrovascular reactivity with 
advancing age. The main findings of this study are that: 1) estrogen treatment had 
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divergent effects on VP-induced cerebrovascular vasoconstriction, 2) age altered the 
specific COX isoform and resultant prostanoids enhanced by estrogen, and 3) estrogen 
enhanced VP-stimulated PGI2 and TXA2 production in both MA and RS, while age 
decreased VP-stimulated PGI2 and increased in TXA2 production in females with 
estrogen replacement.  Taken together, these data reveal that the vascular effects of 
estrogen are distinctly age-dependent.  In younger ovariectomized MA females with 
estrogen replacement, the beneficial and protective effects of estrogen are very evident 
(decreased vasoconstriction, increased dilator function).  Conversely, in older 
ovariectomized RS females with estrogen replacement, the detrimental effects of 
estrogen begin to be manifested (enhanced vasoconstriction, increased constrictor 
prostanoid function). These findings contribute to the understanding of the interactive 
effects of age and estrogen on the modulation of cerebrovascular function.   
 
To determine the roles of age and estrogen on the regulation of VP- induced 
vasoconstriction of female rat middle cerebral artery, the effects of ovariectomy and 
estrogen replacement therapy on vascular reactivity to VP and prostanoid function were 
determined. Plasma concentrations of 17β-estradiol were significantly attenuated by 
ovariectomy in both age groups. Estrogen replacement therapy restored plasma estradiol 
levels to concentrations that did not differ between MA or RS groups and are consistent 
with estradiol levels in intact female rats previously reported (Li et al., 2005; Ospina et 
al., 2002).  
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5.4.1. Age-dependent effects on the modulation of cerebrovascular reactivity 
Endothelial dysfunction increases in men after age 40 and in women after age 55 
(Celermajer et al., 1994). While the exact cause of the decline in endothelial function is 
unknown, aging is usually associated with a reduction in the ability to elicit 
endothelium-dependent vasodilation in both animals and in humans (Csiszar et al., 2002; 
Taddei et al., 2001; Tschudi et al., 1996). This loss of function occurs via numerous 
mechanisms related to nitric oxide-mediated dilation including: increased activity of 
arginase, augmented production of oxygen derived free radicals, reduced expression of 
eNOS, lesser eNOS activity, reduced expression of soluble guanylyl cyclase, and 
decreased nitric oxide release (Csiszar et al., 2002; Kloss et al., 2000; Taddei et al., 
2001; Tschudi et al., 1996). In addition to the age-related changes in nitric oxide, an 
enhancement of vasoconstrictor prostaglandins further potentiates age-dependent 
endothelial dysfunction. Both COX-1 and COX-2 expression are upregulated with 
advancing age (Heymes et al., 2000; Kang et al., 2007; Matz et al., 2000; Numaguchi et 
al., 1999; Stewart et al., 2000; Tang et al., 2008).  In contrast, with advancing age PGI2 
receptor (IP) expression declines, reducing the efficacy of PGI2 that is produced (Ge et 
al., 1995; Numaguchi et al., 1999; Shi et al., 2008; Tang et al., 2008). There is also 
indirect evidence suggesting that untransformed PGH2 is augmented with aging due to 
COX-1/COX-2 upregulation (Dai et al., 1992; Hynes et al., 1987; Lin et al., 1994; 
Pagano et al., 1991). Numerous studies have reported increases in TXA2 and TXS 
mRNA in aorta and mesenteric arteries with age (Matz et al., 2000; Tang et al., 2008).  
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Interestingly, in the current study, advancing age had no effect on VP-induced 
vasoconstriction in ovariectomized rats; however, in estrogen replaced rats, advancing 
age significantly augmented VP-induced vasoconstriction.  Advancing age also altered 
the specific COX isoform and resultant prostanoids enhanced by estrogen; COX-1 in 
younger MA females, COX-2 in older RS females with estrogen replacement.  
Furthermore, advancing age decreased VP-stimulated PGI2 production and increased 
VP-stimulated TXA2 production with estrogen replacement. Thus, in agreement with 
previous studies, the balance of dilator to constrictor prostanoids appears to be altered 
with age, including decreased release and/or reactivity to PGI2 and augmentation of 
constrictor prostanoid PGH2 and TXA2 production. 
 
5.4.2. Effect of estrogen on mechanisms of cerebrovascular reactivity 
Many studies have reported that estrogen enhances the production and/or the sensitivity 
of cerebral arteries to vasodilatory factors nitric oxide and PGI2 (Geary et al., 2000a; 
Geary et al., 1998; Ospina et al., 2003; Ospina et al., 2002; Pelligrino et al., 2000; 
Skarsgard et al., 1997). In the cerebrovasculature, estrogen appears to shift the 
prostaglandin balance towards greater production of vasodilator prostanoids (Ospina et 
al., 2003). In cerebral vessels of young rats, estrogen elevates both COX-1 and PGIS 
resulting in enhanced PGI2 production (Geary et al., 2000a; Ospina et al., 2003; Ospina 
et al., 2002). Interestingly TXA2 production was also shown to be slightly yet 
significantly elevated in young animals with estrogen-treatment, perhaps due to 
increased COX-1 levels (Lin et al., 2002; Ospina et al., 2002).   
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The current study reveals that estrogen is an important regulator of VP-induced 
vasoconstriction of the female rat middle cerebral artery and that the effects of estrogen 
on cerebrovascular reactivity appear to differ with advancing age. In younger MA 
females, estrogen markedly attenuated vasoconstrictor responses to VP. In contrast, in 
older RS females, estrogen significantly augmented cerebrovascular vasoconstrictor 
responses to VP. Thus, estrogen exerts divergent effects on the modulation of 
cerebrovascular function with advancing age. The second major finding was that 
estrogen enhanced the role of COX-1 and COX-2 prostanoid pathways in VP-induced 
cerebrovascular vasoconstriction. In younger MA females with estrogen replacement, 
SC560 reduced reactivity to a greater extent than NS398, indicating that COX-1 derived 
prostanoids were dominant. In contrast, in older RS females receiving estrogen 
replacement this effect was reversed with NS398 attenuating contraction by a greater 
extent than SC560, suggesting a dominant role for COX-2 derived prostanoids with 
advancing age. Furthermore, VP-stimulated PGI2 and TXA2 production were enhanced 
significantly by estrogen replacement in both younger and older ovariectomized females. 
Taken together with results from the functional data, the attenuation of VP-induced 
vasoconstriction in younger MA females appears to be due to estrogen-enhanced 
production of PGI2, while the age-dependent augmentation of vasoconstriction in older 
females is due to enhanced production of TXA2.  These data provide evidence that 
estrogen exerts different effects depending on age.  In younger females, estrogen 
replacement therapy is beneficial; yet, in older females, estrogen replacement therapy is 
detrimental. These findings help to explain why estrogen is beneficial and 
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neuroprotective in young animals but deleterious in postmenopausal women. The age- 
and estrogen-dependent shifts in dilator and constrictor prostanoids observed in the 
present study reveal important novel roles for estrogen and prostanoids in 
cerebrovascular function during aging not previously reported.  
 
5.4.3. Beneficial and deleterious effects of estrogen and age on cerebrovascular function 
Earlier findings of human epidemiological (Kawas et al., 1997; Levy et al., 1988; 
Messerli et al., 1987) and experimental animal studies (Farhat et al., 1996; Karas, 2002; 
Simpkins et al., 1997) led to the belief that estrogen replacement therapy exerts 
beneficial effects on neurological and cardiovascular health and is protective against 
diseases such as dementia, coronary artery disease, hypertension, and stroke. An 
abundance of evidence from experimental animal studies has established that estrogen 
does exert beneficial or protective effects on the cerebrovasculature by reducing vascular 
reactivity and thereby increasing blood flow through nitric oxide- and vasodilator 
prostanoid-dependent mechanisms (Geary et al., 2000a; Geary et al., 1998; McNeill et 
al., 1999; McNeill et al., 2002; Orshal et al., 2004; Osanai et al., 2000; Ospina et al., 
2003; Ospina et al., 2002). In contrast, more recent human epidemiological findings 
such as the HERS (Hulley et al., 1998), HERSII (Grady et al., 2000; Hulley et al., 
2002), and WHI studies (Hendrix et al., 2006; Wassertheil-Smoller et al., 2003) all 
suggest that in older women estrogen replacement therapy increases the incidences of 
neurological (dementia and stroke) and vascular diseases (coronary artery disease, 
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hypertension, and venous thrombosis). Thus, the role of estrogen in cardiovascular 
health and disease has become controversial.  
 
Numerous studies have revealed age-related changes in vascular function due to 
increases in oxidative stress.  Advancing age impairs eNOS-dependent vasodilation by 
increases in superoxide formation via activation of NADPH oxidase in pial arterioles 
from male rats (Mayhan et al., 2008). Similar studies in the cerebral vasculature of 
young and aged female rats showed that estrogen replacement therapy significantly 
reduced bacterial lipopolysaccharide induced increases in iNOS and COX-2 formation in 
young but not in older animals (Sunday et al., 2007). Since both iNOS and COX-2 can 
lead to the formation of ROS, vasoconstrictor tone of cerebral vessels would thus be 
enhanced in aged as compared to younger female rats. Age-dependent decreases in the 
coupled state of NOS may also occur. In the uncoupled state, NOS catalyzes NADPH to 
superoxide ion, rather than producing nitric oxide.  Additionally, there is evidence that 
aging reduces the levels of L-arginine (Berkowitz et al., 2003) and tetrahydrobiopterin 
(Carlstrom et al., 2009) providing a greater potential for uncoupling of NOS and 
increased production of superoxide (White et al., 2005). These findings provide a clear 
mechanistic explanation for an age-dependent change in the effects of estrogen on the 
vascular wall, from the beneficial expression of eNOS and formation of nitric oxide in 
younger animals to the uncoupling of eNOS and the deleterious formation of superoxide 
in older animals. In summary, in younger females, estrogen leads to the formation of 
beneficial or protective substances such as nitric oxide; however, with advancing age 
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estrogen therapy may result in the formation of detrimental substances including 
increased formation of superoxide and other ROS. 
 
Although multiple studies have demonstrated beneficial effects of estrogen replacement 
in numerous vascular beds of young animals (Geary et al., 2000a; Li et al., 2008; Ospina 
et al., 2003), this is the first study to compare the effects of estrogen replacement in 
female rats of younger and more advanced age. Further understanding of the 
mechanisms underlying the effects of age and estrogen on the regulation of 
cerebrovascular function will aid in the knowledge of their contributions in 
pathophysiological states such as stroke. 
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6. SUMMARY AND CONCLUSIONS 
 
The purpose of this dissertation was to investigate the role of two therapeutic 
interventions (exercise training and hormone replacement therapy) on differing states of 
endothelial dysfunction (chronic coronary occlusion and aging). The first project utilized 
a model of chronic coronary artery occlusion to evaluate the effects of exercise training 
on cellular and molecular adaptations of the nonoccluded control and collateral-
dependent coronary vasculature.  The second project utilized a model of aging to 
evaluate the interactive effects of age and hormone replacement therapy on the cellular 
mechanisms underlying the regulation of cerebrovascular function. 
 
6.1. Normal endothelial function 
Under normal conditions, the vascular endothelium regulates of a number of important 
vascular functions, including thrombosis, smooth muscle cell proliferation, vascular 
tone, cell migration, leukocyte adhesion, and inflammatory responses, by producing 
numerous endothelium-derived vasoactive mediators (Feletou et al., 2006; Landmesser 
et al., 2004; Vane et al., 1990; Vanhoutte et al., 2009).  In response to mechanical or 
humoral stimuli, the endothelium releases several agents that regulate vascular function, 
including: nitric oxide, PGI2, EDHFs, TXA2, and ROS. The release of nitric oxide and 
other vascular mediators by endothelial cells can be modulated by both acute and 
chronic factors. Enhanced secretion or up-regulation of vascular mediators occurs via 
increased shear stress, hormones, exercise, and diet, while decreased secretion or down-
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regulation occurs via oxidative stress, smoking, obesity, and vascular diseases 
(Vanhoutte et al., 2009). 
 
6.2. Endothelial dysfunction 
Endothelial dysfunction is exhibited in many disease states including coronary artery 
disease, hypertension, and diabetes, and is also associated with advancing age. It is 
characterized by a decrease in nitric oxide bioavailability (decreased synthesis or 
increased degradation) and an increase in the production of constrictor prostanoids. 
Endothelial dysfunction alters vascular health in multiple ways including decreased 
nitric oxide bioactivity, increased superoxide production, attenuation of endothelium-
dependent dilation, increased vascular tone, and atherogenesis (Feletou et al., 2006; 
Lyons, 1997; Vanhoutte, 1997; Vanhoutte, 1998; Vanhoutte et al., 2009). The loss of 
nitric oxide bioavailability is a key manifestation of endothelial dysfunction that 
contributes to the pathogenesis and clinical expression of many disease states. Its 
presence predicts the severity of outcome, particularly the occurrence of myocardial 
infarction and stroke (Suwaidi et al., 2000; Vanhoutte, 1997).   
 
6.2.1. Chronic coronary occlusion 
Endothelial dysfunction is a key characteristic of cardiovascular disease. Its presence 
predicts the severity of outcome, particularly the occurrence of myocardial infarction 
(Suwaidi et al., 2000; Vanhoutte, 1997). In patients with coronary artery disease, 
treatment with aspirin (COX inhibitor) and a TP receptor antagonist results in improved 
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endothelial function (Belhassen et al., 2003; Husain et al., 1998). These findings suggest 
that endothelium-derived prostanoids contribute to endothelial dysfunction in patients 
with coronary artery disease. Additionally, decreased synthesis and/or increased 
degradation leads to a decrease in the bioavailability of nitric oxide, which is a key 
manifestation of endothelial dysfunction that contributes to the pathogenesis of 
atherosclerosis (Vita, 2011).  
 
The effects of chronic coronary occlusion on coronary vascular function were examined 
in the first project of this dissertation.  Interestingly there were no significant differences 
between the collateral-dependent LCX and nonoccluded control LAD of sedentary 
animals.  This suggests that collateral-development was sufficient enough to provide 
adequate flow into the compromised LCX artery to maintain normal function. 
 
6.2.2. Aging 
Endothelial dysfunction increases in men after age 40 and in women after age 55 
(Celermajer et al., 1994). While the exact causes of age-dependent decreases in 
endothelial function are unknown, aging is usually associated with a reduction in the 
ability of the endothelium to elicit endothelium-dependent vasodilation in both animals 
and humans (Csiszar et al., 2002; Taddei et al., 2001; Tschudi et al., 1996). This loss of 
function occurs via numerous mechanisms related to nitric oxide-mediated dilation 
including: increased activity of arginase, augmented production of oxygen derived free 
radicals, reduced expression of eNOS, lower eNOS activity, reduced expression of 
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soluble guanylyl cyclase, and decreased nitric oxide release (Csiszar et al., 2002; Kloss 
et al., 2000; Taddei et al., 2001; Tschudi et al., 1996). Numerous studies have revealed 
age-related changes in vascular function due to increases in oxidative stress.  Advancing 
age impairs eNOS-dependent vasodilation by increases in superoxide formation via 
activation of NAD(P)H oxidase in pial arterioles from male rats (Mayhan et al., 2008). 
Additionally, estrogen replacement therapy significantly reduced bacterial 
lipopolysaccharide induced increases in iNOS and COX-2 formation in young but not in 
older animals (Sunday et al., 2007), leading to increased formation of ROS, and 
enhanced vasoconstrictor tone of cerebral vessels with advancing age. Aging reduces the 
levels of L-arginine (Berkowitz et al., 2003) and tetrahydrobiopterin (Carlstrom et al., 
2009) providing a greater potential for uncoupling of NOS and increased production of 
superoxide (White et al., 2005) rather than nitric oxide. These findings provide a clear 
mechanistic explanation for an age-dependent change in the effects of estrogen on the 
vascular wall, from the beneficial expression of eNOS and formation of nitric oxide in 
younger animals to the uncoupling of eNOS and the deleterious formation of superoxide 
in older animals.  
 
In addition, an enhancement of vasoconstrictor prostanoids potentiates age-dependent 
endothelial dysfunction. With advancing age, both COX-1 and COX-2 expression are 
upregulated by oxidative stress. Furthermore, PGI2 receptor (IP) expression decreases 
with age (Ge et al., 1995; Numaguchi et al., 1999; Shi et al., 2008; Tang et al., 2008). 
There is indirect evidence suggesting that untransformed PGH2 is also augmented with 
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aging due to COX-1 and/or COX-2 upregulation (Dai et al., 1992; Hynes et al., 1987; 
Lin et al., 1994; Pagano et al., 1991). Numerous studies have shown increases in TXA2 
and TXS mRNA in aorta and mesenteric arteries with age (Matz et al., 2000; Tang et al., 
2008). Thus, the balance of dilator to constrictor prostanoids is altered with age, 
involving decreased sensitivity to PGI2 and enhanced production of constrictor 
prostanoids PGH2 and TXA2, which eventually leads to endothelial dysfunction. 
 
The effects of advancing age on cerebrovascular function were examined in the second 
project of this dissertation.  First, the effects of age and sex on VP-induced 
vasoconstriction were examined using intact male and female Sprague-Dawley rats of 
two age groups. Interestingly, VP-induced vasoconstriction was enhanced with age in 
intact female but was unchanged in male rats.  In intact rats of both sexes, selective 
blockade of COX-1 or COX-2 pathways produced age-dependent changes in 
cerebrovascular reactivity to VP. Additionally, VP-stimulated PGI2 and TXA2 
production significantly decreased with age in intact females but was unchanged in 
males. Second, the mechanisms underlying the effects of age and estrogen on VP-
induced vasoconstriction were examined using ovariectomized and estrogen-replaced 
female Sprague-Dawley rats of two age groups. Age had no effect on VP-induced 
vasoconstriction in ovariectomized rats; however, in estrogen replaced rats, advancing 
age significantly augmented VP-mediated vasoconstriction.  Advancing age also altered 
the specific COX isoform and resultant prostanoids enhanced by estrogen; COX-1 in 
younger MA females, COX-2 in older RS females with estrogen replacement.  
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Furthermore, advancing age decreased VP-stimulated PGI2 production and increased 
VP-stimulated TXA2 production in female rats with estrogen replacement.  
  
6.3. Effects of therapeutic interventions on endothelial function 
Numerous therapeutic interventions, including antioxidants, lipid-lowering drugs, 
exercise, and hormone replacement therapy, are known to improve coronary and 
peripheral endothelial function.  
 
6.3.1 Exercise training 
The effect of exercise on the vascular health of patients with coronary artery disease is of 
considerable interest and the benefits of regular exercise following a cardiac event are 
quite significant. Exercise-based cardiac rehabilitation for patients with CAD decreases 
total mortality by 20% and cardiac mortality by 26% (Taylor et al., 2004). Participation 
in a comprehensive cardiac exercise-based rehabilitation program leads to a significant 
reduction in cardiac events and hospital readmissions and a significant increase in 
functional capacity (Ades et al., 1997; Hedback et al., 2001).  
 
The first project of this dissertation examined the therapeutic intervention of exercise 
training.  The results from these studies revealed the novel finding that exercise training 
enhances multiple mechanisms of endothelium-dependent vascular relaxation which 
appear to function in a compensatory manner rather than in an additive fashion. 
Bradykinin-stimulated nitric oxide levels were significantly increased after exercise 
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training in endothelial cells of both nonoccluded and collateral-dependent arteries. 
Bradykinin treatment significantly increased PGI2 levels in all artery treatment groups 
and PGI2 production tended to be further enhanced after NOS inhibition in exercise-
trained pigs. There was no effect of chronic occlusion or exercise training on K
+
 channel 
or BKCa channel currents. Furthermore, there was no effect of occlusion or exercise 
training on BKCa channel protein levels in these studies. In contrast, the effect of IBTX 
in the functional data suggests that BKCa channels do contribute to the enhanced 
relaxation after exercise. Taken together, these data suggest that a bradykinin-sensitive 
cellular signaling pathway that mediates smooth muscle relaxation via BKCa channels 
may be upregulated by exercise training and contribute to enhanced relaxation, rather 
than an increase in BKCa channel protein.  This pathway may be a putative EDHF since 
the contribution of BKCa channels persisted in the presence of NOS and prostanoid 
inhibition. Interestingly, despite increases in these signaling molecules with exercise 
training, bradykinin-mediated, endothelium-dependent relaxation was not enhanced in 
arteries from exercise-trained pigs. Bradykinin-mediated relaxation was, however, more 
persistent in arteries from exercise-trained pigs after inhibition of select endothelium-
dependent signaling molecules, suggesting redundancy in signaling pathways of vascular 
relaxation. These data provide evidence that multiple vasodilators contribute to exercise 
training-enhanced endothelium-dependent relaxation in coronary arteries of hearts 
exposed to chronic occlusion. Although redundant, upregulation of multiple parallel 
regulatory systems may provide more refined control of blood flow after exercise 
training. 
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6.3.2. Hormone replacement therapy 
Since the late 1900s, estrogen has been known to exert neuroprotective effects in animal 
models of cerebral ischemia or stroke. Younger premenopausal women are protected 
from ischemic stroke as compared to males, yet this protective effect is lost after 
menopause. Additionally, premenopausal women experience less damage and greater 
functional and cognitive recovery from neurologic insult than males. Because of these 
findings, as well as supporting evidence from animal studies, exposure to estrogen was 
postulated to be neuroprotective. In 2000, an estimated 10 million women were 
receiving HRT for the alleviation of menopausal symptoms. However, after just a few 
years, reports from WHI indicated that estrogen therapy significantly increased 
incidence and severity of stroke. Thus, it is important to examine why estrogen is 
beneficial and neuroprotective in young animals but not in postmenopausal women. 
 
The second project of this dissertation examined the therapeutic intervention of hormone 
replacement therapy.  The results from these studies revealed the novel finding that 
estrogen is an important regulator of the constrictor responses of the female rat middle 
cerebral artery to VP and that its effects on cerebrovascular reactivity appear to differ 
with advancing age. In younger MA females, estrogen markedly attenuated 
vasoconstrictor responses to VP. In contrast, in older RS females, estrogen significantly 
augmented cerebrovascular vasoconstrictor responses to VP. Thus, estrogen exerts 
divergent effects on the modulation of cerebrovascular function with advancing age. The 
second major finding was that estrogen enhanced the role of COX-1 and COX-2 
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mediated prostanoid pathways in VP-induced cerebrovascular vasoconstriction. In 
younger MA females with estrogen replacement, SC560 reduced reactivity to a greater 
extent than NS398, indicating that COX-1 prostanoids were dominant. In contrast, in 
older RS females receiving estrogen replacement this effect was reversed with NS398 
attenuating contraction by a greater extent than SC560, suggesting a dominant role for 
COX-2 prostanoids with advancing age. Furthermore, VP-stimulated PGI2 and TXA2 
production were enhanced significantly by estrogen replacement in both younger and 
older ovariectomized females. Taken together with results from the functional data, the 
attenuation of VP-induced vasoconstriction in younger MA females appears to be due to 
estrogen-enhanced production of PGI2, while the age-dependent augmentation of 
vasoconstriction in older females is due to enhanced production of TXA2.  These data 
provide evidence that estrogen exerts different effects depending on age.  In younger 
females, estrogen replacement therapy is beneficial; yet, in older females, estrogen 
replacement therapy is detrimental. These findings begin to explain why estrogen is 
beneficial and neuroprotective in young animals but not in postmenopausal women.  
 
6.4. Clinical significance 
Despite remarkable evidence for the therapeutic benefits of physical activity, the 
mechanisms by which regular exercise improves vascular function in the setting of 
coronary artery disease are not fully understood. The findings from this study provide 
new evidence that exercise training concomitantly enhances the contribution of multiple 
vasodilating mechanisms, including nitric oxide, prostacyclin and BKCa channels, to 
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vascular function in ischemic heart disease. Increased contribution of multiple 
vasodilator signaling pathways after exercise training appears to promote compensation 
or redundancy to ensure adequate vasodilation and maintenance of coronary blood flow. 
The results from this project further understanding of the mechanisms underlying 
coronary vascular adaptations to exercise in health and coronary artery disease. 
 
Similarly, the mechanisms underlying the beneficial effects of estrogen on 
cerebrovascular function have been studied at length, while the mechanisms responsible 
for age-dependent deleterious effects of estrogen are largely unknown. Furthermore, the 
effects of advancing age and estrogen replacement on the modulation of cerebrovascular 
function are poorly understood. This lack of understanding emphasizes the importance 
of examining the cellular and molecular mechanisms underlying the role of age in the 
deleterious effects of estrogen replacement therapy and endogenous estrogen on the 
cerebral vasculature. The results of this study reveal important and novel information 
regarding the effects of estrogen and advancing age on cerebrovascular function. Further 
understanding of the mechanisms by which estrogen exerts beneficial versus detrimental 
effects on the cerebrovasculature will perhaps lead to new gender-specific therapeutic 
agents designed specifically to target the cerebrovascular system and other estrogen-
responsive tissues. 
 
In summary, the goal of this dissertation research was to investigate the role of two 
therapeutic interventions (exercise training and hormone replacement therapy) on two 
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states of endothelial dysfunction (chronic coronary occlusion and aging). The 
progression from a healthy functional endothelium to a dysfunctional endothelium 
underlies the development of numerous cardiovascular diseases. In humans, all major 
cardiovascular risk factors, including hypercholesterolemia, hypertension, diabetes, and 
smoking, have been associated with endothelial dysfunction. The use of therapeutic 
interventions to restore endothelial function to a healthy state is a major area of clinical 
interest. A further understanding of the mechanisms underlying the beneficial effects of 
these therapeutic interventions will aid in developing better clinical treatments of 
endothelial dysfunction which underlie many states of disease. 
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